<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Nilutamide</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Nilutamide">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Nilutamide</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Nilutamide</b>, sold under the brand names <b>Nilandron</b> and <b>Anandron</b>, is a nonsteroidal antiandrogen (NSAA) which is used in the treatment of prostate cancer.<span class="mw-ref" id="cite_ref-Nilandron-Label_7-0"><a href="#cite_note-Nilandron-Label-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-Elks2014_8-0"><a href="#cite_note-Elks2014-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_9-0"><a href="#cite_note-IndexNominum2000-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-MortonHall2012_10-0"><a href="#cite_note-MortonHall2012-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_11-0"><a href="#cite_note-Drugs.com-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span><span class="mw-ref" id="cite_ref-DenisGriffiths1999_12-0"><a href="#cite_note-DenisGriffiths1999-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> It has also been studied as a component of feminizing hormone therapy for transgender women and to treat acne and seborrhea in women.<span class="mw-ref" id="cite_ref-Denis2012a_13-0"><a href="#cite_note-Denis2012a-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-KreukelsSteensma2013_14-0"><a href="#cite_note-KreukelsSteensma2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-pmid2744186_15-0"><a href="#cite_note-pmid2744186-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-pmid2462132_16-0"><a href="#cite_note-pmid2462132-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> It is taken by mouth.<span class="mw-ref" id="cite_ref-LemkeWilliams2012_4-5"><a href="#cite_note-LemkeWilliams2012-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Nilutamide</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Nilutamide.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Nilutamide.svg.png" data-file-width="512" data-file-height="379" data-file-type="drawing" height="167" width="225"></figure-inline></td></tr><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Nilutamide_molecule_ball.png" tppabs="https://ptable.com/wiki/compounds/I/m/Nilutamide_molecule_ball.png" data-file-width="2000" data-file-height="1668" data-file-type="bitmap" height="188" width="225"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td>nye-LOO-tah-mide<span class="mw-ref" id="cite_ref-LiverTox_1-0"><a href="#cite_note-LiverTox-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Nilandron, Anandron</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Other names</th><td>RU-23908</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/nilutamide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/nilutamide.html'" tppabs="https://www.drugs.com/monograph/nilutamide.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a697044.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a697044.html'" tppabs="https://medlineplus.gov/druginfo/meds/a697044.html" class="external text external">a697044</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr>:</small><span> </span>C (Risk not ruled out)<span> </span><span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth<span class="mw-ref" id="cite_ref-PerryDoll2012_3-0"><a href="#cite_note-PerryDoll2012-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Drug class</th><td>Nonsteroidal antiandrogen</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L02BB02<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L02BB02  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L02BB02'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L02BB02" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li>In<span>&nbsp;</span>general: ℞<span>&nbsp;</span>(Prescription only)</li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>Good<span class="mw-ref" id="cite_ref-PerryDoll2012_3-1"><a href="#cite_note-PerryDoll2012-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>80–84%<span class="mw-ref" id="cite_ref-LemkeWilliams2012_4-0"><a href="#cite_note-LemkeWilliams2012-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Liver (CYP2C19, <abbr>FMO</abbr>)<span class="mw-ref" id="cite_ref-PerryDoll2012_3-2"><a href="#cite_note-PerryDoll2012-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-LemkeWilliams2012_4-1"><a href="#cite_note-LemkeWilliams2012-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolites</th><td>At least 5, some active<span class="mw-ref" id="cite_ref-LemkeWilliams2012_4-2"><a href="#cite_note-LemkeWilliams2012-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><span class="mw-ref" id="cite_ref-ChabnerLongo2010_5-0"><a href="#cite_note-ChabnerLongo2010-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>Mean: 56 hours (~2 days)<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_6-0"><a href="#cite_note-KolvenbagFurr2009-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><br>Range: 23–87 hours<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_6-1"><a href="#cite_note-KolvenbagFurr2009-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Urine: 62%<span class="mw-ref" id="cite_ref-PerryDoll2012_3-3"><a href="#cite_note-PerryDoll2012-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-LemkeWilliams2012_4-3"><a href="#cite_note-LemkeWilliams2012-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span><br>Feces: &lt;10%<span class="mw-ref" id="cite_ref-PerryDoll2012_3-4"><a href="#cite_note-PerryDoll2012-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-LemkeWilliams2012_4-4"><a href="#cite_note-LemkeWilliams2012-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">5,5-Dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]imidazolidine-2,4-dione</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=63612-50-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=63612-50-0'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=63612-50-0" class="external text external">63612-50-0</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/4493  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/4493'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/4493" class="external text external">4493</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2864  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2864'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2864" class="external text external">2864</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00665  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00665'" tppabs="https://www.drugbank.ca/drugs/DB00665" class="external text external">DB00665</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.4337.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.4337.html'" tppabs="http://www.chemspider.com/Chemical-Structure.4337.html" class="external text external">4337</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=51G6I8B902  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=51G6I8B902'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=51G6I8B902" class="external text external">51G6I8B902</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D00965  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D00965'" tppabs="https://www.kegg.jp/entry/D00965" class="external text external">D00965</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEBI</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7573  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7573'" tppabs="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:7573" class="external text external">CHEBI:7573</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1274  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1274'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1274" class="external text external">ChEMBL1274</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID3034165  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID3034165'" tppabs="https://comptox.epa.gov/dashboard/DTXSID3034165" class="external text external">DTXSID3034165</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.153.268  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.153.268'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.153.268" class="external text external">100.153.268</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>12</sub><span>H</span><sub>10</sub><span>F</span><sub>3</sub><span>N</span><sub>3</sub><span>O</span><sub>4</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">317.224</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=CC1%28C%28%3DO%29N%28C%28%3DO%29N1%29C2%3DCC%28%3DC%28C%3DC2%29%5BN%2B%5D%28%3DO%29%5BO-%5D%29C%28F%29%28F%29F%29C  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=CC1%28C%28%3DO%29N%28C%28%3DO%29N1%29C2%3DCC%28%3DC%28C%3DC2%29%5BN%2B%5D%28%3DO%29%5BO-%5D%29C%28F%29%28F%29F%29C'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=CC1%28C%28%3DO%29N%28C%28%3DO%29N1%29C2%3DCC%28%3DC%28C%3DC2%29%5BN%2B%5D%28%3DO%29%5BO-%5D%29C%28F%29%28F%29F%29C" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Melting point</th><td>149<span>&nbsp;</span>°C (300<span>&nbsp;</span>°F)</td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">CC1(C(=O)N(C(=O)N1)C2=CC(=C(C=C2)[N+](=O)[O-])C(F)(F)F)C</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:XWXYUMMDTVBTOU-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=462261036&page2=Nilutamide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=462261036&page2=Nilutamide'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=462261036&page2=Nilutamide" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Side effects in men include breast tenderness and enlargement, feminization, sexual dysfunction, and hot flashes.<span class="mw-ref" id="cite_ref-pmid8997470_17-0"><a href="#cite_note-pmid8997470-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-Dart2004_18-0"><a href="#cite_note-Dart2004-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-MDMD2008_19-0"><a href="#cite_note-MDMD2008-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-Lehne2013_20-0"><a href="#cite_note-Lehne2013-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Nausea, vomiting, visual disturbances, alcohol intolerance, elevated liver enzymes, and lung disease can occur in both sexes.<span class="mw-ref" id="cite_ref-Lehne2013_20-1"><a href="#cite_note-Lehne2013-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-Becker2001_21-0"><a href="#cite_note-Becker2001-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span><span class="mw-ref" id="cite_ref-Dart2004_18-1"><a href="#cite_note-Dart2004-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-WeinKavoussi2011_22-0"><a href="#cite_note-WeinKavoussi2011-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span><span class="mw-ref" id="cite_ref-Jafri2014_23-0"><a href="#cite_note-Jafri2014-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-BoarderNewby2010_24-0"><a href="#cite_note-BoarderNewby2010-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span> Rarely, nilutamide can cause respiratory failure and liver damage.<span class="mw-ref" id="cite_ref-pmid8997470_17-1"><a href="#cite_note-pmid8997470-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span><span class="mw-ref" id="cite_ref-Lehne2013_20-2"><a href="#cite_note-Lehne2013-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> These unfavorable side effects, along with a number of associated cases of death, have limited the use of nilutamide.<span class="mw-ref" id="cite_ref-DenisGriffiths1999_12-1"><a href="#cite_note-DenisGriffiths1999-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-DeVitaLawrence2016_25-0"><a href="#cite_note-DeVitaLawrence2016-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span><span class="mw-ref" id="cite_ref-Chang2005_26-0"><a href="#cite_note-Chang2005-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>


<p>Nilutamide acts as a selective antagonist of the androgen receptor (AR), preventing the effects of androgens like <a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">testosterone</a> and <a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">dihydrotestosterone</a> (DHT) in the body.<span class="mw-ref" id="cite_ref-SinghGauthier2000_27-0"><a href="#cite_note-SinghGauthier2000-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span><span class="mw-ref" id="cite_ref-Denis2012a_13-1"><a href="#cite_note-Denis2012a-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> Because most prostate cancer cells rely on these hormones for growth and survival, nilutamide can slow the progression of prostate cancer and extend life in men with the disease.<span class="mw-ref" id="cite_ref-Denis2012a_13-2"><a href="#cite_note-Denis2012a-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


<p>Nilutamide was discovered in 1977 and was first introduced for medical use in 1987.<span class="mw-ref" id="cite_ref-Elks2014_8-1"><a href="#cite_note-Elks2014-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-LabrieLagacé1978_28-0"><a href="#cite_note-LabrieLagacé1978-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span><span class="mw-ref" id="cite_ref-pmid385986_29-0"><a href="#cite_note-pmid385986-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span><span class="mw-ref" id="cite_ref-KolvenbagFurr2009_6-2"><a href="#cite_note-KolvenbagFurr2009-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> It became available in the United States in 1996.<span class="mw-ref" id="cite_ref-Pavlik2012_30-0"><a href="#cite_note-Pavlik2012-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-BohlGao2005_31-0"><a href="#cite_note-BohlGao2005-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-AdisInsight_32-0"><a href="#cite_note-AdisInsight-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span> The drug has largely been replaced by newer and improved NSAAs, namely <a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">bicalutamide</a> and enzalutamide, due to their better efficacy, tolerability, and safety, and is now rarely used.<span class="mw-ref" id="cite_ref-Gulley2011_33-0"><a href="#cite_note-Gulley2011-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span></p>

<style data-mw-deduplicate="TemplateStyles:r886046785">.mw-parser-output .toclimit-2 .toclevel-1 ul,.mw-parser-output .toclimit-3 .toclevel-2 ul,.mw-parser-output .toclimit-4 .toclevel-3 ul,.mw-parser-output .toclimit-5 .toclevel-4 ul,.mw-parser-output .toclimit-6 .toclevel-5 ul,.mw-parser-output .toclimit-7 .toclevel-6 ul{display:none}</style><div class="toclimit-3"><meta property="mw:PageProp/toc"></div>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Prostate_cancer">Prostate cancer</h3></summary>
    
<p>Nilutamide is used in prostate cancer in combination with a <a href="Gonadotropin-releasing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">gonadotropin-releasing hormone</a> (GnRH) analogue at a dosage of 300<span>&nbsp;</span>mg/day (150<span>&nbsp;</span>mg twice daily) for the first 4 weeks of treatment, and 150<span>&nbsp;</span>mg/day thereafter.<span class="mw-ref" id="cite_ref-Chang2005_26-1"><a href="#cite_note-Chang2005-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span><span class="mw-ref" id="cite_ref-Upfal2006_34-0"><a href="#cite_note-Upfal2006-34" style="counter-reset: mw-Ref 34;"><span class="mw-reflink-text">[34]</span></a></span> It is not indicated as a monotherapy in prostate cancer.<span class="mw-ref" id="cite_ref-Chang2005_26-2"><a href="#cite_note-Chang2005-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> Only one small non-comparative study has assessed nilutamide as a monotherapy in prostate cancer.<span class="mw-ref" id="cite_ref-pmid12603397_35-0"><a href="#cite_note-pmid12603397-35" style="counter-reset: mw-Ref 35;"><span class="mw-reflink-text">[35]</span></a></span></p>

<p>Nilutamide has been used to prevent the effects of the <a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">testosterone</a> flare at the start of GnRH agonist therapy in men with prostate cancer.<span class="mw-ref" id="cite_ref-pmid16986003_36-0"><a href="#cite_note-pmid16986003-36" style="counter-reset: mw-Ref 36;"><span class="mw-reflink-text">[36]</span></a></span><span class="mw-ref" id="cite_ref-pmid8481213_37-0"><a href="#cite_note-pmid8481213-37" style="counter-reset: mw-Ref 37;"><span class="mw-reflink-text">[37]</span></a></span><span class="mw-ref" id="cite_ref-pmid2503723_38-0"><a href="#cite_note-pmid2503723-38" style="counter-reset: mw-Ref 38;"><span class="mw-reflink-text">[38]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Transgender_hormone_therapy">Transgender hormone therapy</h3></summary>
    
<p>Nilutamide has been studied for use as a component of feminizing hormone therapy for transgender women.<span class="mw-ref" id="cite_ref-Denis2012a_13-3"><a href="#cite_note-Denis2012a-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span><span class="mw-ref" id="cite_ref-KreukelsSteensma2013_14-1"><a href="#cite_note-KreukelsSteensma2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span> It has been assessed in at least five small clinical studies for this purpose in treatment-naive subjects.<span class="mw-ref" id="cite_ref-KreukelsSteensma2013_14-2"><a href="#cite_note-KreukelsSteensma2013-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-AsschemanGooren1989_39-0"><a href="#cite_note-AsschemanGooren1989-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span><span class="mw-ref" id="cite_ref-Raode_Voogt1988_40-0"><a href="#cite_note-Raode_Voogt1988-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-van_KemenadeCohen-Kettenis1989_41-0"><a href="#cite_note-van_KemenadeCohen-Kettenis1989-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-GoorenSpinder1987_42-0"><a href="#cite_note-GoorenSpinder1987-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span><span class="mw-ref" id="cite_ref-De_VoogtRao1987_43-0"><a href="#cite_note-De_VoogtRao1987-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span> In these studies, nilutamide monotherapy at a dosage of 300<span>&nbsp;</span>mg/day, induced observable signs of clinical feminization in young transgender women (age range 19–33 years) within 8 weeks,<span class="mw-ref" id="cite_ref-Raode_Voogt1988_40-1"><a href="#cite_note-Raode_Voogt1988-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span> including breast development, decreased body hair (though not facial hair),<span class="mw-ref" id="cite_ref-AsschemanGooren1989_39-1"><a href="#cite_note-AsschemanGooren1989-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span> decreased morning erections and sex drive,<span class="mw-ref" id="cite_ref-van_KemenadeCohen-Kettenis1989_41-1"><a href="#cite_note-van_KemenadeCohen-Kettenis1989-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span> and positive psychological and emotional changes.<span class="mw-ref" id="cite_ref-van_KemenadeCohen-Kettenis1989_41-2"><a href="#cite_note-van_KemenadeCohen-Kettenis1989-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span><span class="mw-ref" id="cite_ref-Cohen-KettenisGooren1993_44-0"><a href="#cite_note-Cohen-KettenisGooren1993-44" style="counter-reset: mw-Ref 44;"><span class="mw-reflink-text">[44]</span></a></span> Signs of breast development occurred in all subjects within 6 weeks and were associated with increased nipple sensitivity,<span class="mw-ref" id="cite_ref-De_VoogtRao1987_43-1"><a href="#cite_note-De_VoogtRao1987-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-Raode_Voogt1988_40-2"><a href="#cite_note-Raode_Voogt1988-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-van_KemenadeCohen-Kettenis1989_41-3"><a href="#cite_note-van_KemenadeCohen-Kettenis1989-41" style="counter-reset: mw-Ref 41;"><span class="mw-reflink-text">[41]</span></a></span> and along with decreased hair growth, were the earliest sign of feminization.<span class="mw-ref" id="cite_ref-Raode_Voogt1988_40-3"><a href="#cite_note-Raode_Voogt1988-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></p>

<p>Nilutamide did not change the size of the prostate gland (which is the same as with high-dosage cyproterone acetate and ethinylestradiol treatment for as long as 18<span>&nbsp;</span>months), but was found to alter its histology, including increased stromal tissue with a significant reduction in acini and atrophic epithelial cells, indicating glandular atrophy.<span class="mw-ref" id="cite_ref-GoorenSpinder1987_42-1"><a href="#cite_note-GoorenSpinder1987-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span><span class="mw-ref" id="cite_ref-De_VoogtRao1987_43-2"><a href="#cite_note-De_VoogtRao1987-43" style="counter-reset: mw-Ref 43;"><span class="mw-reflink-text">[43]</span></a></span><span class="mw-ref" id="cite_ref-AdisInternational1993_45-0"><a href="#cite_note-AdisInternational1993-45" style="counter-reset: mw-Ref 45;"><span class="mw-reflink-text">[45]</span></a></span> In addition, readily apparent histological changes were observed in the testes, including a reduction in tubular and interstitial cells.<span class="mw-ref" id="cite_ref-GoorenSpinder1987_42-2"><a href="#cite_note-GoorenSpinder1987-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span></p>

<p>Nilutamide was found to more than double <a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone">luteinizing hormone</a> (LH) and <a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">testosterone</a> levels and to triple <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a> levels.<span class="mw-ref" id="cite_ref-AsschemanGooren1989_39-2"><a href="#cite_note-AsschemanGooren1989-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span><span class="mw-ref" id="cite_ref-Raode_Voogt1988_40-4"><a href="#cite_note-Raode_Voogt1988-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-GoorenSpinder1987_42-3"><a href="#cite_note-GoorenSpinder1987-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> In contrast, follicle-stimulating hormone levels remained unchanged.<span class="mw-ref" id="cite_ref-Raode_Voogt1988_40-5"><a href="#cite_note-Raode_Voogt1988-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-GoorenSpinder1987_42-4"><a href="#cite_note-GoorenSpinder1987-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> A slight but significant increase in prolactin levels was observed, and levels of sex hormone-binding globulin increased as well.<span class="mw-ref" id="cite_ref-Raode_Voogt1988_40-6"><a href="#cite_note-Raode_Voogt1988-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span><span class="mw-ref" id="cite_ref-GoorenSpinder1987_42-5"><a href="#cite_note-GoorenSpinder1987-42" style="counter-reset: mw-Ref 42;"><span class="mw-reflink-text">[42]</span></a></span> The addition of ethinylestradiol to nilutamide therapy after 8 weeks abolished the increase in LH, testosterone, and estradiol levels and dramatically suppressed testosterone levels, into the castrate range.<span class="mw-ref" id="cite_ref-AsschemanGooren1989_39-3"><a href="#cite_note-AsschemanGooren1989-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span><span class="mw-ref" id="cite_ref-Raode_Voogt1988_40-7"><a href="#cite_note-Raode_Voogt1988-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span> Both nilutamide alone and the combination of nilutamide and estrogen were regarded as resulting in effective and favorable antiandrogen action and feminization in transgender women.<span class="mw-ref" id="cite_ref-AsschemanGooren1989_39-4"><a href="#cite_note-AsschemanGooren1989-39" style="counter-reset: mw-Ref 39;"><span class="mw-reflink-text">[39]</span></a></span><span class="mw-ref" id="cite_ref-Raode_Voogt1988_40-8"><a href="#cite_note-Raode_Voogt1988-40" style="counter-reset: mw-Ref 40;"><span class="mw-reflink-text">[40]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Skin_conditions">Skin conditions</h3></summary>
    
<p>Nilutamide has been assessed in the treatment of acne and seborrhea in women in at least one small clinical study.<span class="mw-ref" id="cite_ref-pmid2744186_15-1"><a href="#cite_note-pmid2744186-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-pmid2462132_16-1"><a href="#cite_note-pmid2462132-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> The dosage used was 200<span>&nbsp;</span>mg/day, and in the study, "seborrhea and acne decreased markedly within the first month and practically disappeared after 2 months of [nilutamide] treatment."<span class="mw-ref" id="cite_ref-pmid2744186_15-2"><a href="#cite_note-pmid2744186-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-pmid2462132_16-2"><a href="#cite_note-pmid2462132-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Available_forms">Available forms</h3></summary>
    
<p>Nilutamide is available in the form of 50 and 150<span>&nbsp;</span>mg oral tablets.<span class="mw-ref" id="cite_ref-Meyers2018_46-0"><a href="#cite_note-Meyers2018-46" style="counter-reset: mw-Ref 46;"><span class="mw-reflink-text">[46]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Side_effects">Side effects</h2></summary>
    
<p>General side effects of NSAAs, including nilutamide, include gynecomastia, breast pain/tenderness, hot flashes (67%), depression, fatigue, sexual dysfunction (including loss of libido and erectile dysfunction), decreased muscle mass, and decreased bone mass with an associated increase in fractures.<span class="mw-ref" id="cite_ref-Dart2004_18-2"><a href="#cite_note-Dart2004-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span><span class="mw-ref" id="cite_ref-MDMD2008_19-1"><a href="#cite_note-MDMD2008-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-Lehne2013_20-3"><a href="#cite_note-Lehne2013-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Also, nausea (24–27%), vomiting, constipation (20%), and insomnia (16%) may occur with nilutamide.<span class="mw-ref" id="cite_ref-Lehne2013_20-4"><a href="#cite_note-Lehne2013-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span> Nilutamide monotherapy is known to eventually induce gynecomastia in 40 to 80% of men treated with it for prostate cancer, usually within 6 to 9<span>&nbsp;</span>months of treatment initiation.<span class="mw-ref" id="cite_ref-Bautista-VidalBarnoiu2014_47-0"><a href="#cite_note-Bautista-VidalBarnoiu2014-47" style="counter-reset: mw-Ref 47;"><span class="mw-reflink-text">[47]</span></a></span><span class="mw-ref" id="cite_ref-DeepinderBraunstein2012_48-0"><a href="#cite_note-DeepinderBraunstein2012-48" style="counter-reset: mw-Ref 48;"><span class="mw-reflink-text">[48]</span></a></span><span class="mw-ref" id="cite_ref-MichalopoulosKeshtgar2012_49-0"><a href="#cite_note-MichalopoulosKeshtgar2012-49" style="counter-reset: mw-Ref 49;"><span class="mw-reflink-text">[49]</span></a></span><span class="mw-ref" id="cite_ref-pmid16321765_50-0"><a href="#cite_note-pmid16321765-50" style="counter-reset: mw-Ref 50;"><span class="mw-reflink-text">[50]</span></a></span></p>

<p>Relative to other NSAAs, nilutamide has been uniquely associated with mild and reversible visual disturbances (31–58%) including delayed ocular adaptation to darkness and impaired color vision,<span class="mw-ref" id="cite_ref-Becker2001_21-1"><a href="#cite_note-Becker2001-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span> a <a href="Disulfiram.htm" tppabs="https://ptable.com/wiki/compounds/A/Disulfiram" title="Disulfiram">disulfiram</a>-like<span class="mw-ref" id="cite_ref-Dart2004_18-3"><a href="#cite_note-Dart2004-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> alcohol intolerance (19%), interstitial pneumonitis (0.77–2.4%)<span class="mw-ref" id="cite_ref-Gulley2011_33-1"><a href="#cite_note-Gulley2011-33" style="counter-reset: mw-Ref 33;"><span class="mw-reflink-text">[33]</span></a></span><span class="mw-ref" id="cite_ref-CamusIII2010_51-0"><a href="#cite_note-CamusIII2010-51" style="counter-reset: mw-Ref 51;"><span class="mw-reflink-text">[51]</span></a></span><span class="mw-ref" id="cite_ref-Held-Warmkessel2006_52-0"><a href="#cite_note-Held-Warmkessel2006-52" style="counter-reset: mw-Ref 52;"><span class="mw-reflink-text">[52]</span></a></span> (which can result in dyspnea (1%) as a secondary effect and can progress to pulmonary fibrosis),<span class="mw-ref" id="cite_ref-WeinKavoussi2011_22-1"><a href="#cite_note-WeinKavoussi2011-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> and hepatitis (1%), and has a higher incidence of nausea and vomiting compared to other NSAAs.<span class="mw-ref" id="cite_ref-DenisGriffiths1999_12-2"><a href="#cite_note-DenisGriffiths1999-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-Chang2005_26-3"><a href="#cite_note-Chang2005-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span><span class="mw-ref" id="cite_ref-Lehne2013_20-5"><a href="#cite_note-Lehne2013-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span><span class="mw-ref" id="cite_ref-RamonDenis2007_53-0"><a href="#cite_note-RamonDenis2007-53" style="counter-reset: mw-Ref 53;"><span class="mw-reflink-text">[53]</span></a></span> The incidence of interstitial pneumonitis with nilutamide has been found to be much higher in Japanese patients (12.6%), warranting particular caution in Asian individuals.<span class="mw-ref" id="cite_ref-Mahler1996_54-0"><a href="#cite_note-Mahler1996-54" style="counter-reset: mw-Ref 54;"><span class="mw-reflink-text">[54]</span></a></span><span class="mw-ref" id="cite_ref-Micromedex2003_55-0"><a href="#cite_note-Micromedex2003-55" style="counter-reset: mw-Ref 55;"><span class="mw-reflink-text">[55]</span></a></span> There is a case report of simultaneous liver and lung toxicity in a nilutamide-treated patient.<span class="mw-ref" id="cite_ref-pmid1580304_56-0"><a href="#cite_note-pmid1580304-56" style="counter-reset: mw-Ref 56;"><span class="mw-reflink-text">[56]</span></a></span></p>

<p>There is also a risk of hepatoxicity with nilutamide, though occurrence is very rare and the risk is significantly less than with flutamide.<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_6-3"><a href="#cite_note-KolvenbagFurr2009-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2009_57-0"><a href="#cite_note-Aronson2009-57" style="counter-reset: mw-Ref 57;"><span class="mw-reflink-text">[57]</span></a></span> The incidence of abnormal liver function tests (e.g., elevated liver enzymes) has been variously reported as 2 to 33% with nilutamide.<span class="mw-ref" id="cite_ref-pmid10388026_58-0"><a href="#cite_note-pmid10388026-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span><span class="mw-ref" id="cite_ref-LiverTox_1-1"><a href="#cite_note-LiverTox-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> For comparison, the risk of elevated liver enzymes has been reported as 4 to 62% in the case of <a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">flutamide</a>.<span class="mw-ref" id="cite_ref-pmid10388026_58-1"><a href="#cite_note-pmid10388026-58" style="counter-reset: mw-Ref 58;"><span class="mw-reflink-text">[58]</span></a></span><span class="mw-ref" id="cite_ref-Jafri2014_23-1"><a href="#cite_note-Jafri2014-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-KolvenbagFurr2009_6-4"><a href="#cite_note-KolvenbagFurr2009-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> The risk of hepatotoxicity with nilutamide has been described as far less than with flutamide.<span class="mw-ref" id="cite_ref-LiverTox_1-2"><a href="#cite_note-LiverTox-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Fulminant hepatic failure has been reported for nilutamide, with fatal outcome.<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_6-5"><a href="#cite_note-KolvenbagFurr2009-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-Aronson2011_59-0"><a href="#cite_note-Aronson2011-59" style="counter-reset: mw-Ref 59;"><span class="mw-reflink-text">[59]</span></a></span><span class="mw-ref" id="cite_ref-pmid8977826_60-0"><a href="#cite_note-pmid8977826-60" style="counter-reset: mw-Ref 60;"><span class="mw-reflink-text">[60]</span></a></span><span class="mw-ref" id="cite_ref-MerwatKabbani2008_61-0"><a href="#cite_note-MerwatKabbani2008-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span> Between 1986 and 2003, the numbers of published cases of hepatotoxicity for antiandrogens totaled 46 for flutamide, 21 for cyproterone acetate, 4 for nilutamide, and 1 for <a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">bicalutamide</a>.<span class="mw-ref" id="cite_ref-ChitturiFarrell2013_62-0"><a href="#cite_note-ChitturiFarrell2013-62" style="counter-reset: mw-Ref 62;"><span class="mw-reflink-text">[62]</span></a></span> Similarly to flutamide, nilutamide exhibits mitochondrial toxicity in hepatocytes by inhibiting respiratory complex I (NADH ubiquinone oxidoreductase) (though not respiratory complexes II, III, or IV) in the electron transport chain, resulting in reduced <a href="Adenosine_triphosphate.htm" tppabs="https://ptable.com/wiki/compounds/A/Adenosine_triphosphate" title="Adenosine triphosphate">ATP</a> and <a href="Glutathione.htm" tppabs="https://ptable.com/wiki/compounds/A/Glutathione" title="Glutathione">glutathione</a> production and thus decreased hepatocyte survival.<span class="mw-ref" id="cite_ref-MerwatKabbani2008_61-1"><a href="#cite_note-MerwatKabbani2008-61" style="counter-reset: mw-Ref 61;"><span class="mw-reflink-text">[61]</span></a></span><span class="mw-ref" id="cite_ref-pmid8035313_63-0"><a href="#cite_note-pmid8035313-63" style="counter-reset: mw-Ref 63;"><span class="mw-reflink-text">[63]</span></a></span><span class="mw-ref" id="cite_ref-CoeJia2007_64-0"><a href="#cite_note-CoeJia2007-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span> The nitro group of nilutamide has been theorized to be involved in both its hepatotoxicity and its pulmonary toxicity.<span class="mw-ref" id="cite_ref-CoeJia2007_64-1"><a href="#cite_note-CoeJia2007-64" style="counter-reset: mw-Ref 64;"><span class="mw-reflink-text">[64]</span></a></span><span class="mw-ref" id="cite_ref-BoelsterliHo2006_65-0"><a href="#cite_note-BoelsterliHo2006-65" style="counter-reset: mw-Ref 65;"><span class="mw-reflink-text">[65]</span></a></span></p>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap"> Side effects of combined androgen blockade with nilutamide and surgical castration</caption>
<tbody><tr>
<th>Class</th><th>Side effect</th><th>Nilutamide 150<span>&nbsp;</span>mg/day + <br>orchiectomy (n = 225) (%)<sup>a,b</sup></th><th>Placebo + orchi-<br>ectomy (n = 232) (%)<sup>a,b</sup></th></tr>
<tr>
<td>Cardiovascular system</td><td>Hypertension</td><td>5.3</td><td>2.6</td></tr>
<tr>
<td rowspan="2">Digestive system</td><td>Nausea</td><td>9.8</td><td>6.0</td></tr>
<tr>
<td>Constipation</td><td>7.1</td><td>3.9</td></tr>
<tr>
<td>Endocrine system</td><td>Hot flashes</td><td>28.4</td><td>22.4</td></tr>
<tr>
<td rowspan="2">Metabolic and nutritional system</td><td>Increased aspartate transaminase</td><td>8.0</td><td>3.9</td></tr>
<tr>
<td>Increased alanine transaminase</td><td>7.6</td><td>4.3</td></tr>
<tr>
<td>Nervous system</td><td>Dizziness</td><td>7.1</td><td>3.4</td></tr>
<tr>
<td>Respiratory system</td><td>Dyspnea</td><td>6.2</td><td>7.3</td></tr>
<tr>
<td rowspan="2">Special senses</td><td>Impaired adaptation to darkness</td><td>12.9</td><td>1.3</td></tr>
<tr>
<td>Abnormal vision</td><td>6.7</td><td>1.7</td></tr>
<tr>
<td>Urogenital system</td><td>Urinary tract infection</td><td>8.0</td><td>9.1</td></tr>
<tr>
<td colspan="2">Overall</td><td>86</td><td>81</td></tr>
<tr>
<td colspan="4" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = Phase III studies of combined androgen blockade (nilutamide + orchiectomy) in men with advanced prostate cancer. <sup>b</sup> = Incidence ≥5% regardless of causality. <b>Sources:</b> See template.</td></tr>
</tbody></table>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="font-size:small; text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap"> <span style="font-size:105%;">Side effects of combined androgen blockade with nilutamide and a GnRH agonist</span></caption>
<tbody><tr>
<th>Class</th><th>Side effect</th><th>Nilutamide 150<span>&nbsp;</span>mg/day + <br><a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a> (n = 209) (%)<sup>a,b</sup></th><th>Placebo + <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leupro-<br>relin</a> (n = 202) (%)<sup>a,b</sup></th></tr>
<tr>
<td rowspan="8">Body as a whole</td><td>Pain</td><td>26.8</td><td>27.7</td></tr>
<tr>
<td>Headache</td><td>13.9</td><td>10.4</td></tr>
<tr>
<td>Asthenia</td><td>19.1</td><td>20.8</td></tr>
<tr>
<td>Back pain</td><td>11.5</td><td>16.8</td></tr>
<tr>
<td>Abdominal pain</td><td>10.0</td><td>5.4</td></tr>
<tr>
<td>Chest pain</td><td>7.2</td><td>4.5</td></tr>
<tr>
<td>Flu syndrome</td><td>7.2</td><td>3.0</td></tr>
<tr>
<td>Fever</td><td>5.3</td><td>6.4</td></tr>
<tr>
<td>Cardiovascular system</td><td>Hypertension</td><td>9.1</td><td>9.9</td></tr>
<tr>
<td rowspan="5">Digestive system</td><td>Nausea</td><td>23.9</td><td>8.4</td></tr>
<tr>
<td>Constipation</td><td>19.6</td><td>16.8</td></tr>
<tr>
<td>Anorexia</td><td>11.0</td><td>6.4</td></tr>
<tr>
<td>Dyspepsia</td><td>6.7</td><td>4.5</td></tr>
<tr>
<td>Vomiting</td><td>5.7</td><td>4.0</td></tr>
<tr>
<td rowspan="3">Endocrine system</td><td>Hot flashes</td><td>66.5</td><td>59.4</td></tr>
<tr>
<td>Erectile dysfunction</td><td>11.0</td><td>12.9</td></tr>
<tr>
<td>Decreased libido</td><td>11.0</td><td>4.5</td></tr>
<tr>
<td>Hemic and lymphatic system</td><td>Anemia</td><td>7.2</td><td>6.4</td></tr>
<tr>
<td rowspan="3">Metabolic and nutritional system</td><td>Increased aspartate transaminase</td><td>12.9</td><td>13.9</td></tr>
<tr>
<td>Peripheral edema</td><td>12.4</td><td>17.3</td></tr>
<tr>
<td>Increased alanine transaminase</td><td>9.1</td><td>8.9</td></tr>
<tr>
<td>Musculoskeletal system</td><td>Bone pain</td><td>6.2</td><td>5.0</td></tr>
<tr>
<td rowspan="4">Nervous system</td><td>Insomnia</td><td>16.3</td><td>15.8</td></tr>
<tr>
<td>Dizziness</td><td>10.0</td><td>11.4</td></tr>
<tr>
<td>Depression</td><td>8.6</td><td>7.4</td></tr>
<tr>
<td>Hypesthesia</td><td>5.3</td><td>2.0</td></tr>
<tr>
<td rowspan="3">Respiratory system</td><td>Dyspnea</td><td>10.5</td><td>7.4</td></tr>
<tr>
<td>Upper respiratory infection</td><td>8.1</td><td>10.9</td></tr>
<tr>
<td>Pneumonia</td><td>5.3</td><td>3.5</td></tr>
<tr>
<td rowspan="4">Skin and appendages</td><td>Sweating</td><td>6.2</td><td>3.0</td></tr>
<tr>
<td>Decreased body hair</td><td>5.7</td><td>0.5</td></tr>
<tr>
<td>Dry skin</td><td>5.3</td><td>2.5</td></tr>
<tr>
<td>Rash</td><td>5.3</td><td>4.0</td></tr>
<tr>
<td rowspan="4">Special senses</td><td>Impaired adaptation to darkness</td><td>56.9</td><td>5.4</td></tr>
<tr>
<td>Chromatopsia</td><td>8.6</td><td>0.0</td></tr>
<tr>
<td>Impaired adaptation to light</td><td>7.7</td><td>1.0</td></tr>
<tr>
<td>Abnormal vision</td><td>6.2</td><td>4.5</td></tr>
<tr>
<td rowspan="6">Urogenital system</td><td>Testicular atrophy</td><td>16.3</td><td>12.4</td></tr>
<tr>
<td>Gynecomastia</td><td>10.5</td><td>11.9</td></tr>
<tr>
<td>Urinary tract infection</td><td>8.6</td><td>21.3</td></tr>
<tr>
<td>Hematuria</td><td>8.1</td><td>7.9</td></tr>
<tr>
<td>Urinary tract disorder</td><td>7.2</td><td>10.4</td></tr>
<tr>
<td>Nocturia</td><td>6.7</td><td>6.4</td></tr>
<tr>
<td colspan="2">Overall</td><td>99.5</td><td>98.5</td></tr>
<tr>
<td colspan="4" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = Phase III studies of combined androgen blockade (nilutamide + GnRH agonist) in men with advanced prostate cancer. <sup>b</sup> = Incidence ≥5% regardless of causality. <b>Sources:</b> See template.</td></tr>
</tbody></table>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Pharmacology">Pharmacology</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacodynamics">Pharmacodynamics</h3></summary>
    


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Antiandrogenic_activity">Antiandrogenic activity</h4></summary>
    
<span>
</span><table class="wikitable floatright" style="text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption> Affinities of selected androgen receptor ligands</caption>
<tbody><tr>
<th>Compound</th><th><abbr>AR</abbr> <abbr>RBA</abbr> (%)</th></tr>
<tr>
<td><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></td><td>100</td></tr>
<tr>
<td>Dihydrotestosterone</td><td>85</td></tr>
<tr>
<td>Cyproterone acetate</td><td>7.8</td></tr>
<tr>
<td><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></td><td>1.4</td></tr>
<tr>
<td>Nilutamide</td><td>0.9</td></tr>
<tr>
<td>Hydroxyflutamide</td><td>0.57</td></tr>
<tr>
<td><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></td><td>&lt;0.0057</td></tr>
<tr class="sortbottom">
<td colspan="3" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Notes:</b> Human prostate tissue used for the assays. <b>Sources:</b> See template.</td></tr>
</tbody></table>

<p>Nilutamide acts as a selective competitive silent antagonist of the AR (IC<sub>50</sub> = 412<span>&nbsp;</span>nM),<span class="mw-ref" id="cite_ref-SinghGauthier2000_27-1"><a href="#cite_note-SinghGauthier2000-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> which prevents androgens like testosterone and DHT from activating the receptor.<span class="mw-ref" id="cite_ref-Denis2012a_13-4"><a href="#cite_note-Denis2012a-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> The affinity of nilutamide for the AR is about 1 to 4% of that of testosterone and is similar to that of <a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">bicalutamide</a> and 2-hydroxyflutamide.<span class="mw-ref" id="cite_ref-Gaillard1996_66-0"><a href="#cite_note-Gaillard1996-66" style="counter-reset: mw-Ref 66;"><span class="mw-reflink-text">[66]</span></a></span><span class="mw-ref" id="cite_ref-FiggChau2010_67-0"><a href="#cite_note-FiggChau2010-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span><span class="mw-ref" id="cite_ref-BenniVemer1990_68-0"><a href="#cite_note-BenniVemer1990-68" style="counter-reset: mw-Ref 68;"><span class="mw-reflink-text">[68]</span></a></span> Similarly to 2-hydroxyflutamide, but unlike bicalutamide, nilutamide is able to weakly activate the AR at high concentrations.<span class="mw-ref" id="cite_ref-FiggChau2010_67-1"><a href="#cite_note-FiggChau2010-67" style="counter-reset: mw-Ref 67;"><span class="mw-reflink-text">[67]</span></a></span> It does not inhibit 5α-reductase.<span class="mw-ref" id="cite_ref-pmid3331376_69-0"><a href="#cite_note-pmid3331376-69" style="counter-reset: mw-Ref 69;"><span class="mw-reflink-text">[69]</span></a></span></p>

<p>Like other NSAAs such as flutamide and bicalutamide, nilutamide, without concomitant GnRH analogue therapy, increases serum androgen (by two-fold in the case of testosterone), <a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">estrogen</a>, and prolactin levels due to inhibition of AR-mediated suppression of steroidogenesis via negative feedback on the hypothalamic–pituitary–gonadal axis.<span class="mw-ref" id="cite_ref-Denis2012a_13-5"><a href="#cite_note-Denis2012a-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> As such, though nilutamide is still effective as an antiandrogen as a monotherapy, it is given in combination with a GnRH analogue such as <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a> in prostate cancer to suppress androgen concentrations to castrate levels in order to attain maximal androgen blockade (MAB).<span class="mw-ref" id="cite_ref-Denis2012a_13-6"><a href="#cite_note-Denis2012a-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>

<p>Like flutamide and bicalutamide, nilutamide is able to cross the blood–brain barrier and has central antiandrogen actions.<span class="mw-ref" id="cite_ref-RaynaudBonne1979_70-0"><a href="#cite_note-RaynaudBonne1979-70" style="counter-reset: mw-Ref 70;"><span class="mw-reflink-text">[70]</span></a></span></p>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="text-align:left; margin-left:auto; margin-right:auto; border:none;">
<caption class="nowrap"> Relative affinities (%) of antiandrogens at steroid-hormone receptors</caption>
<tbody><tr>
<th>Antiandrogen</th><th><abbr>AR</abbr></th><th><abbr>PR</abbr></th><th><abbr>ER</abbr></th><th><abbr>GR</abbr></th><th><abbr>MR</abbr></th></tr>
<tr>
<td>Cyproterone acetate</td><td>8–10</td><td>60</td><td>&lt;0.1</td><td>5</td><td>1</td></tr>
<tr>
<td>Chlormadinone acetate</td><td>5</td><td>175</td><td>&lt;0.1</td><td>38</td><td>1</td></tr>
<tr>
<td>Megestrol acetate</td><td>5</td><td>152</td><td>&lt;0.1</td><td>50</td><td>3</td></tr>
<tr>
<td><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></td><td>7</td><td>0.4<sup>a</sup></td><td>&lt;0.1</td><td>2<sup>a</sup></td><td>182</td></tr>
<tr>
<td>Trimethyltrienolone</td><td>3.6</td><td>&lt;1</td><td>&lt;1</td><td>&lt;1</td><td>&lt;1</td></tr>
<tr>
<td>Inocoterone</td><td>0.8</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr>
<td>Inocoterone acetate</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr>
<td><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr>
<td>Hydroxyflutamide</td><td>0.5–0.8</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr>
<td>Nilutamide</td><td>0.5–0.8</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr>
<td><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></td><td>1.8</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td><td>&lt;0.1</td></tr>
<tr class="sortbottom">
<td colspan="6" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Notes:</b> (1): Reference ligands (100%) were testosterone for the <abbr>AR</abbr>, progesterone for the <abbr>PR</abbr>, estradiol for the <abbr>ER</abbr>, <a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">dexamethasone</a> for the <abbr>GR</abbr>, and <a href="Aldosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Aldosterone" title="Aldosterone">aldosterone</a> for the <abbr>MR</abbr>. (2): Tissues were rat prostate (AR), rabbit uterus (PR), mouse uterus (ER), rat thymus (GR), and rat kidney (MR). (3): Incubation times (0°C) were 24 hours (AR, <sup>a</sup>), 2 hours (PR, ER), 4 hours (GR), and 1 hour (MR). (4): Assay methods were different for bicalutamide for receptors besides the AR. <b>Sources:</b> See template.</td></tr>
</tbody></table>

<span>
</span><table class="wikitable sortable mw-collapsible mw-collapsed" style="margin-left: auto; margin-right: auto; border: none;">
<caption class="nowrap"> Relative affinities of first-generation nonsteroidal antiandrogens for the androgen receptor</caption>
<tbody><tr>
<th rowspan="2">Species</th><th colspan="3"><abbr>IC<sub>50</sub></abbr> (nM)</th><th colspan="3"><abbr>RBA</abbr> (ratio)</th></tr>
<tr>
<th><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></th><th>2-Hydroxyflutamide</th><th><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></th><th><abbr>Bica</abbr> / <abbr>2-OH-flu</abbr></th><th><abbr>Bica</abbr> / <abbr>nilu</abbr></th><th>Ref</th></tr>
<tr>
<td>Rat</td><td>190</td><td>700</td><td><abbr>ND</abbr></td><td>4.0</td><td><abbr>ND</abbr></td><td><span class="mw-ref" id="cite_ref-pmid3625091_71-0"><a href="#cite_note-pmid3625091-71" style="counter-reset: mw-Ref 71;"><span class="mw-reflink-text">[71]</span></a></span></td></tr>
<tr>
<td>Rat</td><td>~400</td><td>~900</td><td>~900</td><td>2.3</td><td>2.3</td><td><span class="mw-ref" id="cite_ref-pmid8136296Receptor_72-0"><a href="#cite_note-pmid8136296Receptor-72" style="counter-reset: mw-Ref 72;"><span class="mw-reflink-text">[72]</span></a></span></td></tr>
<tr>
<td>Rat</td><td><abbr>ND</abbr></td><td><abbr>ND</abbr></td><td><abbr>ND</abbr></td><td>3.3</td><td><abbr>ND</abbr></td><td><span class="mw-ref" id="cite_ref-pmid2615358_73-0"><a href="#cite_note-pmid2615358-73" style="counter-reset: mw-Ref 73;"><span class="mw-reflink-text">[73]</span></a></span></td></tr>
<tr>
<td>Rat<sup>a</sup></td><td>3595</td><td>4565</td><td>18620</td><td>1.3</td><td>5.2</td><td><span class="mw-ref" id="cite_ref-LuoMartel1996_74-0"><a href="#cite_note-LuoMartel1996-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span></td></tr>
<tr>
<td>Human</td><td>~300</td><td>~700</td><td>~500</td><td>2.5</td><td>1.6</td><td><span class="mw-ref" id="cite_ref-pmid2788775_75-0"><a href="#cite_note-pmid2788775-75" style="counter-reset: mw-Ref 75;"><span class="mw-reflink-text">[75]</span></a></span></td></tr>
<tr>
<td>Human</td><td>~100</td><td>~300</td><td><abbr>ND</abbr></td><td>~3.0</td><td><abbr>ND</abbr></td><td><span class="mw-ref" id="cite_ref-pmid8693644_76-0"><a href="#cite_note-pmid8693644-76" style="counter-reset: mw-Ref 76;"><span class="mw-reflink-text">[76]</span></a></span></td></tr>
<tr>
<td>Human<sup>a</sup></td><td>2490</td><td>2345</td><td>5300</td><td>1.0</td><td>2.1</td><td><span class="mw-ref" id="cite_ref-LuoMartel1996_74-1"><a href="#cite_note-LuoMartel1996-74" style="counter-reset: mw-Ref 74;"><span class="mw-reflink-text">[74]</span></a></span></td></tr>
<tr class="sortbottom">
<td colspan="7" style="width: 1px; background-color:#eaecf0; text-align: center;"><b>Footnotes:</b> <sup>a</sup> = Controversial data. <b>Sources:</b> See template.</td></tr>
</tbody></table>


</details>
<details data-level="4" open="">
    <summary class="section-heading"><h4 id="Cytochrome_P450_inhibition">Cytochrome P450 inhibition</h4></summary>
    
<p>Nilutamide is known to inhibit several cytochrome P450 enzymes, including CYP1A2, CYP2C9, and CYP3A4, and can result in increased levels of medications that are metabolized by these enzymes.<span class="mw-ref" id="cite_ref-FerrandoLevenson2010_77-0"><a href="#cite_note-FerrandoLevenson2010-77" style="counter-reset: mw-Ref 77;"><span class="mw-reflink-text">[77]</span></a></span> It has also been found to inhibit the enzyme CYP17A1 (17α-hydroxylase/17,20-lyase) <i>in vitro</i> and thus the biosynthesis of androgens.<span class="mw-ref" id="cite_ref-HarrisColeman1993_78-0"><a href="#cite_note-HarrisColeman1993-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span><span class="mw-ref" id="cite_ref-pmid2956461_79-0"><a href="#cite_note-pmid2956461-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span> However, nilutamide monotherapy significantly increases testosterone levels <i>in vivo</i>, so the clinical significance of this finding is uncertain.<span class="mw-ref" id="cite_ref-HarrisColeman1993_78-1"><a href="#cite_note-HarrisColeman1993-78" style="counter-reset: mw-Ref 78;"><span class="mw-reflink-text">[78]</span></a></span><span class="mw-ref" id="cite_ref-pmid2956461_79-1"><a href="#cite_note-pmid2956461-79" style="counter-reset: mw-Ref 79;"><span class="mw-reflink-text">[79]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Pharmacokinetics">Pharmacokinetics</h3></summary>
    
<p>Nilutamide has an elimination half-life of 23 to 87 hours, with a mean of 56 hours,<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_6-6"><a href="#cite_note-KolvenbagFurr2009-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> or about two days; this allows for once-daily administration.<span class="mw-ref" id="cite_ref-DenisGriffiths1999_12-3"><a href="#cite_note-DenisGriffiths1999-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span> Steady state (plateau) levels of the drug are attained after two weeks of administration with a dosage of 150<span>&nbsp;</span>mg twice daily (300<span>&nbsp;</span>mg/day total).<span class="mw-ref" id="cite_ref-Denis2012b_80-0"><a href="#cite_note-Denis2012b-80" style="counter-reset: mw-Ref 80;"><span class="mw-reflink-text">[80]</span></a></span> It is metabolized by CYP2C19, with at least five metabolites.<span class="mw-ref" id="cite_ref-ChabnerLongo2010_5-1"><a href="#cite_note-ChabnerLongo2010-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> Virtually all of the antiandrogenic activity of nilutamide comes from the parent drug (as opposed to metabolites).<span class="mw-ref" id="cite_ref-MahlerVerhelst1998_81-0"><a href="#cite_note-MahlerVerhelst1998-81" style="counter-reset: mw-Ref 81;"><span class="mw-reflink-text">[81]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Chemistry">Chemistry</h2></summary>
    
<p>Nilutamide is structurally related to the first-generation NSAAs <a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">flutamide</a> and <a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">bicalutamide</a> as well as to the second-generation NSAAs enzalutamide and apalutamide.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Nilutamide was developed by Roussel and was first described in 1977.<span class="mw-ref" id="cite_ref-Elks2014_8-2"><a href="#cite_note-Elks2014-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-LabrieLagacé1978_28-1"><a href="#cite_note-LabrieLagacé1978-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span><span class="mw-ref" id="cite_ref-pmid385986_29-1"><a href="#cite_note-pmid385986-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span> It was first introduced for medical use in 1987 in France<span class="mw-ref" id="cite_ref-KolvenbagFurr2009_6-7"><a href="#cite_note-KolvenbagFurr2009-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-FischerKlein2018_82-0"><a href="#cite_note-FischerKlein2018-82" style="counter-reset: mw-Ref 82;"><span class="mw-reflink-text">[82]</span></a></span> and was the second NSAA to be marketed, with flutamide preceding it and bicalutamide following it in 1995.<span class="mw-ref" id="cite_ref-DenisGriffiths1999_12-4"><a href="#cite_note-DenisGriffiths1999-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span><span class="mw-ref" id="cite_ref-83"><a href="#cite_note-83" style="counter-reset: mw-Ref 83;"><span class="mw-reflink-text">[83]</span></a></span> It was not introduced until 1996 in the United States.<span class="mw-ref" id="cite_ref-Pavlik2012_30-1"><a href="#cite_note-Pavlik2012-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span><span class="mw-ref" id="cite_ref-BohlGao2005_31-1"><a href="#cite_note-BohlGao2005-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-AdisInsight_32-1"><a href="#cite_note-AdisInsight-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Generic_names">Generic names</h3></summary>
    
<p><i>Nilutamide</i> is the generic name of the drug and its <abbr>INN</abbr>, <abbr>USAN</abbr>, <abbr>BAN</abbr>, and <abbr>DCF</abbr>.<span class="mw-ref" id="cite_ref-Elks2014_8-3"><a href="#cite_note-Elks2014-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span><span class="mw-ref" id="cite_ref-IndexNominum2000_9-1"><a href="#cite_note-IndexNominum2000-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-MortonHall2012_10-1"><a href="#cite_note-MortonHall2012-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_11-1"><a href="#cite_note-Drugs.com-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Brand_names">Brand names</h3></summary>
    
<p>Nilutamide is marketed under the brand name Nilandron in the United States and under the brand name Anandron elsewhere in the world such as in Australia, Canada, Europe, and Latin America.<span class="mw-ref" id="cite_ref-IndexNominum2000_9-2"><a href="#cite_note-IndexNominum2000-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_11-2"><a href="#cite_note-Drugs.com-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Availability">Availability</h3></summary>
    
<p>Nilutamide is or has been available in the United States, Canada, Australia, Europe, Latin America, Egypt, and Lebanon.<span class="mw-ref" id="cite_ref-IndexNominum2000_9-3"><a href="#cite_note-IndexNominum2000-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_11-3"><a href="#cite_note-Drugs.com-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> In Europe, it is or has been available in Belgium, Croatia, the <a href="Czech_Republic.htm" tppabs="https://ptable.com/wiki/compounds/A/Czech_Republic" title="Czech Republic">Czech Republic</a>, Finland, France, the Netherlands, Norway, Poland, Portugal, Serbia, Sweden, Switzerland, and Yugoslavia.<span class="mw-ref" id="cite_ref-IndexNominum2000_9-4"><a href="#cite_note-IndexNominum2000-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_11-4"><a href="#cite_note-Drugs.com-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> in Latin America, it is or has been available in Argentina, Brazil, and Mexico.<span class="mw-ref" id="cite_ref-IndexNominum2000_9-5"><a href="#cite_note-IndexNominum2000-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span><span class="mw-ref" id="cite_ref-Drugs.com_11-5"><a href="#cite_note-Drugs.com-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>The combination of an estrogen and nilutamide as a form of combined androgen blockade for the treatment of prostate cancer has been studied in animals.<span class="mw-ref" id="cite_ref-pmid3420036_84-0"><a href="#cite_note-pmid3420036-84" style="counter-reset: mw-Ref 84;"><span class="mw-reflink-text">[84]</span></a></span></p>

<p>Nilutamide has been studied in the treatment of advanced breast cancer.<span class="mw-ref" id="cite_ref-pmid25665553_85-0"><a href="#cite_note-pmid25665553-85" style="counter-reset: mw-Ref 85;"><span class="mw-reflink-text">[85]</span></a></span><span class="mw-ref" id="cite_ref-pmid1903951_86-0"><a href="#cite_note-pmid1903951-86" style="counter-reset: mw-Ref 86;"><span class="mw-reflink-text">[86]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-LiverTox-1"> <span id="mw-reference-text-cite_note-LiverTox-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://livertox.nih.gov/Nilutamide.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://livertox.nih.gov/Nilutamide.htm'" tppabs="https://livertox.nih.gov/Nilutamide.htm" class="external text external">"Nilutamide - LiverTox"</a>. <i>National Institutes of Health</i><span class="reference-accessdate">. Retrieved <span class="nowrap">24 September</span> 2018</span>. <q>In large registration clinical trials, ALT elevations occurred in 2% to 33% of patients during nilutamide therapy.  The elevations were usually mild, asymptomatic and transient, rarely requiring drug discontinuation.  In rare instances, clinically apparent acute liver injury has occurred during nilutamide therapy, but the number of published cases are few, and the agent appears to be far less hepatotoxic than flutamide.</q></cite></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/nilutamide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/nilutamide.html'" tppabs="https://www.drugs.com/pregnancy/nilutamide.html" class="external text external">"Nilutamide (Nilandron) Use During Pregnancy"</a>.</cite></span></li><li id="cite_note-PerryDoll2012-3"> <span id="mw-reference-text-cite_note-PerryDoll2012-3" class="mw-reference-text"><cite id="CITEREFMichael_C._PerryDonald_C._DollCarl_E._Freter2012" class="citation book cs1">Michael C. Perry; Donald C. Doll; Carl E. Freter (30 July 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=My3SjQTguyYC&pg=PA711  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=My3SjQTguyYC&pg=PA711'" tppabs="https://books.google.com/books?id=My3SjQTguyYC&pg=PA711" class="external text external"><i>Perry's The Chemotherapy Source Book</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>711–. ISBN<span>&nbsp;</span><bdi>978-1-4698-0343-2</bdi>.</cite></span></li><li id="cite_note-LemkeWilliams2012-4"> <span id="mw-reference-text-cite_note-LemkeWilliams2012-4" class="mw-reference-text"><cite id="CITEREFThomas_L._LemkeDavid_A._Williams2012" class="citation book cs1">Thomas L. Lemke; David A. Williams (24 January 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1373  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1373'" tppabs="https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA1373" class="external text external"><i>Foye's Principles of Medicinal Chemistry</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>1373–. ISBN<span>&nbsp;</span><bdi>978-1-60913-345-0</bdi>.</cite></span></li><li id="cite_note-ChabnerLongo2010-5"> <span id="mw-reference-text-cite_note-ChabnerLongo2010-5" class="mw-reference-text"><cite id="CITEREFBruce_A._ChabnerDan_L._Longo2010" class="citation book cs1">Bruce A. Chabner; Dan L. Longo (8 November 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=WL4arNFsQa8C&pg=PA680  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=WL4arNFsQa8C&pg=PA680'" tppabs="https://books.google.com/books?id=WL4arNFsQa8C&pg=PA680" class="external text external"><i>Cancer Chemotherapy and Biotherapy: Principles and Practice</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>680–. ISBN<span>&nbsp;</span><bdi>978-1-60547-431-1</bdi>.</cite></span></li><li id="cite_note-KolvenbagFurr2009-6"> <span id="mw-reference-text-cite_note-KolvenbagFurr2009-6" class="mw-reference-text"><cite id="CITEREFKolvenbagFurr2009" class="citation book cs1">Kolvenbag, Geert J. C. M.; Furr, Barrington J. A. (2009). "Nonsteroidal Antiandrogens".  In V. Craig Jordan; Barrington J. A. Furr (eds.). <i>Hormone Therapy in Breast and Prostate Cancer</i>. Humana Press. pp.<span>&nbsp;</span>347–368. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-1-59259-152-7_16  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-1-59259-152-7_16'" tppabs="https://doi.org/10.1007%2F978-1-59259-152-7_16" class="external text external">10.1007/978-1-59259-152-7_16</a>. ISBN<span>&nbsp;</span><bdi>978-1-60761-471-5</bdi>. <q>Although the t1/2 of nilutamide is  h (mean 56 h) (39), suggesting that once-daily dosing would be appropriate, a three times per day regimen has been employed in most clinical trials.</q></cite></span></li><li id="cite_note-Nilandron-Label-7"> <span id="mw-reference-text-cite_note-Nilandron-Label-7" class="mw-reference-text"><a href="javascript:if(confirm('https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020169s008lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020169s008lbl.pdf'" tppabs="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020169s008lbl.pdf" class="external free external">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020169s008lbl.pdf</a></span></li><li id="cite_note-Elks2014-8"> <span id="mw-reference-text-cite_note-Elks2014-8" class="mw-reference-text"><cite id="CITEREFJ._Elks2014" class="citation book cs1">J. Elks (14 November 2014). <a href="javascript:if(confirm('https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA873  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA873'" tppabs="https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA873" class="external text external"><i>The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies</i></a>. Springer. pp.<span>&nbsp;</span>873–. ISBN<span>&nbsp;</span><bdi>978-1-4757-2085-3</bdi>.</cite></span></li><li id="cite_note-IndexNominum2000-9"> <span id="mw-reference-text-cite_note-IndexNominum2000-9" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA737  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA737'" tppabs="https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA737" class="external text external"><i>Index Nominum 2000: International Drug Directory</i></a>. Taylor &amp; Francis. 2000. pp.<span>&nbsp;</span>737–. ISBN<span>&nbsp;</span><bdi>978-3-88763-075-1</bdi>.</cite></span></li><li id="cite_note-MortonHall2012-10"> <span id="mw-reference-text-cite_note-MortonHall2012-10" class="mw-reference-text"><cite id="CITEREFI.K._MortonJudith_M._Hall2012" class="citation book cs1">I.K. Morton; Judith M. Hall (6 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA199  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA199'" tppabs="https://books.google.com/books?id=tsjrCAAAQBAJ&pg=PA199" class="external text external"><i>Concise Dictionary of Pharmacological Agents: Properties and Synonyms</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>199–. ISBN<span>&nbsp;</span><bdi>978-94-011-4439-1</bdi>.</cite></span></li><li id="cite_note-Drugs.com-11"> <span id="mw-reference-text-cite_note-Drugs.com-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/international/nilutamide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/international/nilutamide.html'" tppabs="https://www.drugs.com/international/nilutamide.html" class="external text external">"Nilutamide"</a>.</cite></span></li><li id="cite_note-DenisGriffiths1999-12"> <span id="mw-reference-text-cite_note-DenisGriffiths1999-12" class="mw-reference-text"><cite id="CITEREFLouis_J_DenisKeith_GriffithsAmir_V_KaisaryGerald_P_Murphy1999" class="citation book cs1">Louis J Denis; Keith Griffiths; Amir V Kaisary; Gerald P Murphy (1 March 1999). <a href="javascript:if(confirm('https://books.google.com/books?id=GreZlojD-tYC&pg=PA280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=GreZlojD-tYC&pg=PA280'" tppabs="https://books.google.com/books?id=GreZlojD-tYC&pg=PA280" class="external text external"><i>Textbook of Prostate Cancer: Pathology, Diagnosis and Treatment: Pathology, Diagnosis and Treatment</i></a>. CRC Press. pp.<span>&nbsp;</span>280–. ISBN<span>&nbsp;</span><bdi>978-1-85317-422-3</bdi>.</cite></span></li><li id="cite_note-Denis2012a-13"> <span id="mw-reference-text-cite_note-Denis2012a-13" class="mw-reference-text"><cite id="CITEREFLouis_Denis2012" class="citation book cs1">Louis Denis (6 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT194  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT194'" tppabs="https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT194" class="external text external"><i>Antiandrogens in Prostate Cancer: A Key to Tailored Endocrine Treatment</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>194–210. ISBN<span>&nbsp;</span><bdi>978-3-642-45745-6</bdi>.</cite></span></li><li id="cite_note-KreukelsSteensma2013-14"> <span id="mw-reference-text-cite_note-KreukelsSteensma2013-14" class="mw-reference-text"><cite id="CITEREFBaudewijntje_P.C._KreukelsThomas_D._SteensmaAnnelou_L.C._de_Vries2013" class="citation book cs1">Baudewijntje P.C. Kreukels; Thomas D. Steensma; Annelou L.C. de Vries (1 July 2013). <a href="javascript:if(confirm('https://books.google.com/books?id=YQ5GAAAAQBAJ&pg=PA280  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=YQ5GAAAAQBAJ&pg=PA280'" tppabs="https://books.google.com/books?id=YQ5GAAAAQBAJ&pg=PA280" class="external text external"><i>Gender Dysphoria and Disorders of Sex Development: Progress in Care and Knowledge</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>280–. ISBN<span>&nbsp;</span><bdi>978-1-4614-7441-8</bdi>.</cite></span></li><li id="cite_note-pmid2744186-15"> <span id="mw-reference-text-cite_note-pmid2744186-15" class="mw-reference-text"><cite id="CITEREFCouzinetThomasThalabardBrailly1989" class="citation journal cs1">Couzinet B, Thomas G, Thalabard JC, Brailly S, Schaison G (1989). "Effects of a pure antiandrogen on gonadotropin secretion in normal women and in polycystic ovarian disease". <i>Fertil. Steril</i>. <b>52</b> (1): 42–50. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fs0015-0282%2816%2960786-0  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fs0015-0282%2816%2960786-0'" tppabs="https://doi.org/10.1016%2Fs0015-0282%2816%2960786-0" class="external text external">10.1016/s0015-0282(16)60786-0</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2744186  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2744186'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2744186" class="external text external">2744186</a>.</cite></span></li><li id="cite_note-pmid2462132-16"> <span id="mw-reference-text-cite_note-pmid2462132-16" class="mw-reference-text"><cite id="CITEREFNamer1988" class="citation journal cs1">Namer M (1988). "Clinical applications of antiandrogens". <i>J. Steroid Biochem</i>. <b>31</b> (4B): 719–29. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2888%2990023-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2888%2990023-4'" tppabs="https://doi.org/10.1016%2F0022-4731%2888%2990023-4" class="external text external">10.1016/0022-4731(88)90023-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2462132  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2462132'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2462132" class="external text external">2462132</a>.</cite></span></li><li id="cite_note-pmid8997470-17"> <span id="mw-reference-text-cite_note-pmid8997470-17" class="mw-reference-text"><cite id="CITEREFDoleHoldsworth1997" class="citation journal cs1">Dole EJ, Holdsworth MT (1997). "Nilutamide: an antiandrogen for the treatment of prostate cancer". <i>Ann Pharmacother</i>. <b>31</b> (1): 65–75. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F106002809703100112  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F106002809703100112'" tppabs="https://doi.org/10.1177%2F106002809703100112" class="external text external">10.1177/106002809703100112</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8997470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8997470'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8997470" class="external text external">8997470</a>.</cite></span></li><li id="cite_note-Dart2004-18"> <span id="mw-reference-text-cite_note-Dart2004-18" class="mw-reference-text"><cite id="CITEREFRichard_C._Dart2004" class="citation book cs1">Richard C. Dart (2004). <a href="javascript:if(confirm('https://books.google.com/books?id=BfdighlyGiwC&pg=PA521  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=BfdighlyGiwC&pg=PA521'" tppabs="https://books.google.com/books?id=BfdighlyGiwC&pg=PA521" class="external text external"><i>Medical Toxicology</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>521–. ISBN<span>&nbsp;</span><bdi>978-0-7817-2845-4</bdi>.</cite></span></li><li id="cite_note-MDMD2008-19"> <span id="mw-reference-text-cite_note-MDMD2008-19" class="mw-reference-text"><cite id="CITEREFLisa_M_DeAngelis_MDJerome_B_Posner_MD2008" class="citation book cs1">Lisa M DeAngelis MD; Jerome B Posner MD (12 September 2008). <a href="javascript:if(confirm('https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479'" tppabs="https://books.google.com/books?id=mpZ8Dp2KdHMC&pg=PA479" class="external text external"><i>Neurologic Complications of Cancer</i></a>. Oxford University Press, USA. pp.<span>&nbsp;</span>479–. ISBN<span>&nbsp;</span><bdi>978-0-19-971055-3</bdi>.</cite></span></li><li id="cite_note-Lehne2013-20"> <span id="mw-reference-text-cite_note-Lehne2013-20" class="mw-reference-text"><cite id="CITEREFRichard_A._Lehne2013" class="citation book cs1">Richard A. Lehne (2013). <a href="javascript:if(confirm('https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297'" tppabs="https://books.google.com/books?id=_4SwO2dHcAIC&pg=PA1297" class="external text external"><i>Pharmacology for Nursing Care</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>1297–. ISBN<span>&nbsp;</span><bdi>978-1-4377-3582-6</bdi>.</cite></span></li><li id="cite_note-Becker2001-21"> <span id="mw-reference-text-cite_note-Becker2001-21" class="mw-reference-text"><cite id="CITEREFKenneth_L._Becker2001" class="citation book cs1">Kenneth L. Becker (2001). <a href="javascript:if(confirm('https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196'" tppabs="https://books.google.com/books?id=FVfzRvaucq8C&pg=PA1196" class="external text external"><i>Principles and Practice of Endocrinology and Metabolism</i></a>. Lippincott Williams &amp; Wilkins. pp.<span>&nbsp;</span>1196–. ISBN<span>&nbsp;</span><bdi>978-0-7817-1750-2</bdi>.</cite></span></li><li id="cite_note-WeinKavoussi2011-22"> <span id="mw-reference-text-cite_note-WeinKavoussi2011-22" class="mw-reference-text"><cite id="CITEREFAlan_J._WeinLouis_R._KavoussiAndrew_C._NovickAlan_W._Partin2011" class="citation book cs1">Alan J. Wein; Louis R. Kavoussi; Andrew C. Novick; Alan W. Partin; Craig A. Peters (25 August 2011). <a href="javascript:if(confirm('https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939'" tppabs="https://books.google.com/books?id=fu3BBwAAQBAJ&pg=PA2939" class="external text external"><i>Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set</i></a>. Elsevier Health Sciences. pp.<span>&nbsp;</span>2939–. ISBN<span>&nbsp;</span><bdi>978-1-4160-6911-9</bdi>.</cite></span></li><li id="cite_note-Jafri2014-23"> <span id="mw-reference-text-cite_note-Jafri2014-23" class="mw-reference-text"><cite id="CITEREFJafri2014" class="citation journal cs1">Jafri, Syed-Mohammed R. (2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966" class="external text external">"Bicalutamide-induced hepatotoxicity: A rare adverse effect"</a>. <i>American Journal of Case Reports</i>. <b>15</b>: 266–270. doi:<a href="javascript:if(confirm('https://doi.org/10.12659%2FAJCR.890679  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.12659%2FAJCR.890679'" tppabs="https://doi.org/10.12659%2FAJCR.890679" class="external text external">10.12659/AJCR.890679</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1941-5923  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1941-5923'" tppabs="https://www.worldcat.org/issn/1941-5923" class="external text external">1941-5923</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068966" class="external text external">4068966</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24967002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24967002'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24967002" class="external text external">24967002</a>.</cite></span></li><li id="cite_note-BoarderNewby2010-24"> <span id="mw-reference-text-cite_note-BoarderNewby2010-24" class="mw-reference-text"><cite id="CITEREFMichael_BoarderDavid_NewbyPhyllis_Navti2010" class="citation book cs1">Michael Boarder; David Newby; Phyllis Navti (25 March 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=KVicAQAAQBAJ&pg=PA632  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=KVicAQAAQBAJ&pg=PA632'" tppabs="https://books.google.com/books?id=KVicAQAAQBAJ&pg=PA632" class="external text external"><i>Pharmacology for Pharmacy and the Health Sciences: A Patient-centred Approach</i></a>. OUP Oxford. pp.<span>&nbsp;</span>632–. ISBN<span>&nbsp;</span><bdi>978-0-19-955982-4</bdi>.</cite></span></li><li id="cite_note-DeVitaLawrence2016-25"> <span id="mw-reference-text-cite_note-DeVitaLawrence2016-25" class="mw-reference-text"><cite id="CITEREFVincent_T._DeVitaTheodore_S._LawrenceSteven_A._Rosenberg2016" class="citation book cs1">Vincent T. DeVita; Theodore S. Lawrence; Steven A. Rosenberg (18 March 2016). <a href="javascript:if(confirm('https://books.google.com/books?id=Bf3DCwAAQBAJ&pg=PT1006  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Bf3DCwAAQBAJ&pg=PT1006'" tppabs="https://books.google.com/books?id=Bf3DCwAAQBAJ&pg=PT1006" class="external text external"><i>Prostate and Other Genitourinary Cancers: Cancer: Principles &amp; Practice of Oncology</i></a>. Wolters Kluwer Health. pp.<span>&nbsp;</span>1006–. ISBN<span>&nbsp;</span><bdi>978-1-4963-5421-1</bdi>.</cite></span></li><li id="cite_note-Chang2005-26"> <span id="mw-reference-text-cite_note-Chang2005-26" class="mw-reference-text"><cite id="CITEREFChawnshang_Chang2005" class="citation book cs1">Chawnshang Chang (1 January 2005). <a href="javascript:if(confirm('https://books.google.com/books?id=4xQAr3Uh8EUC&pg=PA11  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4xQAr3Uh8EUC&pg=PA11'" tppabs="https://books.google.com/books?id=4xQAr3Uh8EUC&pg=PA11" class="external text external"><i>Prostate Cancer: Basic Mechanisms and Therapeutic Approaches</i></a>. World Scientific. pp.<span>&nbsp;</span>11–. ISBN<span>&nbsp;</span><bdi>978-981-256-920-2</bdi>.</cite></span></li><li id="cite_note-SinghGauthier2000-27"> <span id="mw-reference-text-cite_note-SinghGauthier2000-27" class="mw-reference-text"><cite id="CITEREFSinghGauthierLabrie2000" class="citation journal cs1">Singh, Shankar; Gauthier, Sylvain; Labrie, Fernand (2000). "Androgen Receptor Antagonists (Antiandrogens) Structure-Activity Relationships". <i>Current Medicinal Chemistry</i>. <b>7</b> (2): 211–247. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F0929867003375371  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F0929867003375371'" tppabs="https://doi.org/10.2174%2F0929867003375371" class="external text external">10.2174/0929867003375371</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0929-8673  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0929-8673'" tppabs="https://www.worldcat.org/issn/0929-8673" class="external text external">0929-8673</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10637363  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10637363'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10637363" class="external text external">10637363</a>.</cite></span></li><li id="cite_note-LabrieLagacé1978-28"> <span id="mw-reference-text-cite_note-LabrieLagacé1978-28" class="mw-reference-text"><cite id="CITEREFLabrieLagacéFerlandKelly1978" class="citation journal cs1">Labrie, Fernand; Lagacé, Lisette; Ferland, Louise; Kelly, Paul A.; Drouin, Jacques; Massicotte, Jocelyne; Bonne, Claude; Raynaud, Jean-Pierre; Dorrington, Jennifer H. (1978). "Interactions Between LHRH, Sex Steroids and "Inhibin" in the Control of LH and FSH Secretion". <i>International Journal of Andrology</i>. <b>1</b> (s2a): 81–101. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2605.1978.tb00008.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2605.1978.tb00008.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2605.1978.tb00008.x" class="external text external">10.1111/j.1365-2605.1978.tb00008.x</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0105-6263  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0105-6263'" tppabs="https://www.worldcat.org/issn/0105-6263" class="external text external">0105-6263</a>.</cite></span></li><li id="cite_note-pmid385986-29"> <span id="mw-reference-text-cite_note-pmid385986-29" class="mw-reference-text"><cite id="CITEREFRaynaudBonneBoutonLagace1979" class="citation journal cs1">Raynaud JP, Bonne C, Bouton MM, Lagace L, Labrie F (1979). "Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues". <i>J. Steroid Biochem</i>. <b>11</b> (1A): 93–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2879%2990281-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2879%2990281-4'" tppabs="https://doi.org/10.1016%2F0022-4731%2879%2990281-4" class="external text external">10.1016/0022-4731(79)90281-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/385986  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/385986'" tppabs="https://pubmed.ncbi.nlm.nih.gov/385986" class="external text external">385986</a>.</cite></span></li><li id="cite_note-Pavlik2012-30"> <span id="mw-reference-text-cite_note-Pavlik2012-30" class="mw-reference-text"><cite id="CITEREFEdward_J._Pavlik2012" class="citation book cs1">Edward J. Pavlik (6 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=LAnpBwAAQBAJ&pg=PA167  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=LAnpBwAAQBAJ&pg=PA167'" tppabs="https://books.google.com/books?id=LAnpBwAAQBAJ&pg=PA167" class="external text external"><i>Estrogens, Progestins, and Their Antagonists: Health Issues</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>167–. ISBN<span>&nbsp;</span><bdi>978-1-4612-4096-9</bdi>.</cite></span></li><li id="cite_note-BohlGao2005-31"> <span id="mw-reference-text-cite_note-BohlGao2005-31" class="mw-reference-text"><cite id="CITEREFBohlGaoMillerBell2005" class="citation journal cs1">Bohl, C. E.; Gao, W.; Miller, D. D.; Bell, C. E.; Dalton, J. T. (2005). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923" class="external text external">"Structural basis for antagonism and resistance of bicalutamide in prostate cancer"</a>. <i>Proceedings of the National Academy of Sciences</i>. <b>102</b> (17): 6201–6206. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2005PNAS..102.6201B  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2005PNAS..102.6201B'" tppabs="https://ui.adsabs.harvard.edu/abs/2005PNAS..102.6201B" class="external text external">2005PNAS..102.6201B</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1073%2Fpnas.0500381102  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1073%2Fpnas.0500381102'" tppabs="https://doi.org/10.1073%2Fpnas.0500381102" class="external text external">10.1073/pnas.0500381102</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0027-8424  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0027-8424'" tppabs="https://www.worldcat.org/issn/0027-8424" class="external text external">0027-8424</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1087923" class="external text external">1087923</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15833816  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15833816'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15833816" class="external text external">15833816</a>.</cite></span></li><li id="cite_note-AdisInsight-32"> <span id="mw-reference-text-cite_note-AdisInsight-32" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://adisinsight.springer.com/drugs/800004379  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://adisinsight.springer.com/drugs/800004379'" tppabs="http://adisinsight.springer.com/drugs/800004379" class="external text external">"Nilutamide - AdisInsight"</a>.</cite></span></li><li id="cite_note-Gulley2011-33"> <span id="mw-reference-text-cite_note-Gulley2011-33" class="mw-reference-text"><cite id="CITEREFJames_Leonard_Gulley2011" class="citation book cs1">James Leonard Gulley (2011). <a href="javascript:if(confirm('https://books.google.com/books?id=WJkjgbRJe3EC&pg=PT81  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=WJkjgbRJe3EC&pg=PT81'" tppabs="https://books.google.com/books?id=WJkjgbRJe3EC&pg=PT81" class="external text external"><i>Prostate Cancer</i></a>. Demos Medical Publishing. pp.<span>&nbsp;</span>81–. ISBN<span>&nbsp;</span><bdi>978-1-935281-91-7</bdi>.</cite></span></li><li id="cite_note-Upfal2006-34"> <span id="mw-reference-text-cite_note-Upfal2006-34" class="mw-reference-text"><cite id="CITEREFJonathan_Upfal2006" class="citation book cs1">Jonathan Upfal (2006). <a href="javascript:if(confirm('https://books.google.com/books?id=7O9kiqN2q2YC&pg=PA283  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=7O9kiqN2q2YC&pg=PA283'" tppabs="https://books.google.com/books?id=7O9kiqN2q2YC&pg=PA283" class="external text external"><i>The Australian Drug Guide: Every Person's Guide to Prescription and Over-the-counter Medicines, Street Drugs, Vaccines, Vitamins and Minerals...</i></a> Black Inc. pp.<span>&nbsp;</span>283–. ISBN<span>&nbsp;</span><bdi>978-1-86395-174-6</bdi>.</cite></span></li><li id="cite_note-pmid12603397-35"> <span id="mw-reference-text-cite_note-pmid12603397-35" class="mw-reference-text"><cite id="CITEREFAnderson2003" class="citation journal cs1">Anderson J (March 2003). "The role of antiandrogen monotherapy in the treatment of prostate cancer". <i>BJU Int</i>. <b>91</b> (5): 455–61. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1464-410X.2003.04026.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1464-410X.2003.04026.x'" tppabs="https://doi.org/10.1046%2Fj.1464-410X.2003.04026.x" class="external text external">10.1046/j.1464-410X.2003.04026.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/12603397  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/12603397'" tppabs="https://pubmed.ncbi.nlm.nih.gov/12603397" class="external text external">12603397</a>. <q>Trial experience with nilutamide monotherapy is limited to one small non-comparative study involving 26 patients with metastatic disease given nilutamide 100 mg three times daily (the dose used when nilutamide is administered as a component of MAB) [14]. The median progression-free survival in these patients was 9 months, with a median overall survival of 23 months. There have been no comparative trials of nilutamide with other antiandrogens or with castration [15]. The limited available data on nilutamide monotherapy means that no meaningful conclusions about the role of nilutamide in this setting can be determined. Nilutamide is not licensed as monotherapy.</q></cite></span></li><li id="cite_note-pmid16986003-36"> <span id="mw-reference-text-cite_note-pmid16986003-36" class="mw-reference-text"><cite id="CITEREFThompson2001" class="citation journal cs1">Thompson IM (2001). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081" class="external text external">"Flare Associated with LHRH-Agonist Therapy"</a>. <i>Rev Urol</i>. 3 Suppl 3: S10–4. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1476081" class="external text external">1476081</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16986003  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16986003'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16986003" class="external text external">16986003</a>.</cite></span></li><li id="cite_note-pmid8481213-37"> <span id="mw-reference-text-cite_note-pmid8481213-37" class="mw-reference-text"><cite id="CITEREFScaletsckySmith1993" class="citation journal cs1">Scaletscky R, Smith JA (April 1993). "Disease flare with gonadotrophin-releasing hormone (GnRH) analogues. How serious is it?". <i>Drug Saf</i>. <b>8</b> (4): 265–70. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00002018-199308040-00001  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00002018-199308040-00001'" tppabs="https://doi.org/10.2165%2F00002018-199308040-00001" class="external text external">10.2165/00002018-199308040-00001</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8481213  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8481213'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8481213" class="external text external">8481213</a>.</cite></span></li><li id="cite_note-pmid2503723-38"> <span id="mw-reference-text-cite_note-pmid2503723-38" class="mw-reference-text"><cite id="CITEREFKuhnBillebaudNavratilMoulonguet1989" class="citation journal cs1">Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R (August 1989). "Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide)". <i>N. Engl. J. Med</i>. <b>321</b> (7): 413–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM198908173210701  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM198908173210701'" tppabs="https://doi.org/10.1056%2FNEJM198908173210701" class="external text external">10.1056/NEJM198908173210701</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2503723  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2503723'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2503723" class="external text external">2503723</a>.</cite></span></li><li id="cite_note-AsschemanGooren1989-39"> <span id="mw-reference-text-cite_note-AsschemanGooren1989-39" class="mw-reference-text"><cite id="CITEREFAsschemanGoorenPeereboom-Wynia1989" class="citation journal cs1">Asscheman, H.; Gooren, I. J. G.; Peereboom-Wynia, J. D. R. (1989). "Reduction in undesired sexual hair growth with Anandron in male-to-female transsexuals-experiences with a novel androgen receptor blocker". <i>Clinical and Experimental Dermatology</i>. <b>14</b> (5): 361–363. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2230.1989.tb02585.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2230.1989.tb02585.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2230.1989.tb02585.x" class="external text external">10.1111/j.1365-2230.1989.tb02585.x</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0307-6938  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0307-6938'" tppabs="https://www.worldcat.org/issn/0307-6938" class="external text external">0307-6938</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2612040  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2612040'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2612040" class="external text external">2612040</a>.</cite></span></li><li id="cite_note-Raode_Voogt1988-40"> <span id="mw-reference-text-cite_note-Raode_Voogt1988-40" class="mw-reference-text"><cite id="CITEREFRaode_VoogtGeldofGooren1988" class="citation journal cs1">Rao, B.Ramanath; de Voogt, H.J.; Geldof, A.A.; Gooren, L.J.G.; Bouman, F.G. (1988). "Merits and considerations in the use of anti-androgen". <i>Journal of Steroid Biochemistry</i>. <b>31</b> (4): 731–737. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2888%2990024-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2888%2990024-6'" tppabs="https://doi.org/10.1016%2F0022-4731%2888%2990024-6" class="external text external">10.1016/0022-4731(88)90024-6</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0022-4731  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0022-4731'" tppabs="https://www.worldcat.org/issn/0022-4731" class="external text external">0022-4731</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3143862  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3143862'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3143862" class="external text external">3143862</a>.</cite></span></li><li id="cite_note-van_KemenadeCohen-Kettenis1989-41"> <span id="mw-reference-text-cite_note-van_KemenadeCohen-Kettenis1989-41" class="mw-reference-text"><cite id="CITEREFvan_KemenadeCohen-KettenisCohenGooren1989" class="citation journal cs1">van Kemenade, Johannes F. L. M.; Cohen-Kettenis, Peggy T.; Cohen, Leo; Gooren, Louis J. G. (1989). "Effects of the pure antiandrogen RU 23.903 (anandron) on sexuality, aggression, and mood in male-to-female transsexuals". <i>Archives of Sexual Behavior</i>. <b>18</b> (3): 217–228. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2FBF01543196  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2FBF01543196'" tppabs="https://doi.org/10.1007%2FBF01543196" class="external text external">10.1007/BF01543196</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0004-0002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0004-0002'" tppabs="https://www.worldcat.org/issn/0004-0002" class="external text external">0004-0002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2751416  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2751416'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2751416" class="external text external">2751416</a>.</cite></span></li><li id="cite_note-GoorenSpinder1987-42"> <span id="mw-reference-text-cite_note-GoorenSpinder1987-42" class="mw-reference-text"><cite id="CITEREFGoorenSpinderSpijkstraVan_Kessel1987" class="citation journal cs1">Gooren, L.; Spinder, T.; Spijkstra, J. J.; Van Kessel, H.; Smals, A.; Rao, B. R.; Hoogslag, M. (1987). "Sex Steroids and Pulsatile Luteinizing Hormone Release in Men. Studies in Estrogen-Treated Agonadal Subjects and Eugonadal Subjects Treated with a Novel Nonsteroidal Antiandrogen". <i>The Journal of Clinical Endocrinology &amp; Metabolism</i>. <b>64</b> (4): 763–770. doi:<a href="javascript:if(confirm('https://doi.org/10.1210%2Fjcem-64-4-763  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1210%2Fjcem-64-4-763'" tppabs="https://doi.org/10.1210%2Fjcem-64-4-763" class="external text external">10.1210/jcem-64-4-763</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0021-972X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0021-972X'" tppabs="https://www.worldcat.org/issn/0021-972X" class="external text external">0021-972X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3102546  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3102546'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3102546" class="external text external">3102546</a>.</cite></span></li><li id="cite_note-De_VoogtRao1987-43"> <span id="mw-reference-text-cite_note-De_VoogtRao1987-43" class="mw-reference-text"><cite id="CITEREFDe_VoogtRaoGeldofGooren1987" class="citation journal cs1">De Voogt, H. J.; Rao, B. R.; Geldof, A. A.; Gooren, L. J. G.; Bouman, F. G. (1987). "Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate". <i>The Prostate</i>. <b>11</b> (4): 305–311. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fpros.2990110403  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fpros.2990110403'" tppabs="https://doi.org/10.1002%2Fpros.2990110403" class="external text external">10.1002/pros.2990110403</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0270-4137  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0270-4137'" tppabs="https://www.worldcat.org/issn/0270-4137" class="external text external">0270-4137</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2960959  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2960959'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2960959" class="external text external">2960959</a>.</cite></span></li><li id="cite_note-Cohen-KettenisGooren1993-44"> <span id="mw-reference-text-cite_note-Cohen-KettenisGooren1993-44" class="mw-reference-text"><cite id="CITEREFCohen-KettenisGooren1993" class="citation journal cs1">Cohen-Kettenis, Peggy T.; Gooren, Louis J.G. (1993). "The Influence of Hormone Treatment on Psychological Functioning of Transsexuals". <i>Journal of Psychology &amp; Human Sexuality</i>. <b>5</b> (4): 55–67. doi:<a href="javascript:if(confirm('https://doi.org/10.1300%2FJ056v05n04_04  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1300%2FJ056v05n04_04'" tppabs="https://doi.org/10.1300%2FJ056v05n04_04" class="external text external">10.1300/J056v05n04_04</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0890-7064  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0890-7064'" tppabs="https://www.worldcat.org/issn/0890-7064" class="external text external">0890-7064</a>.</cite></span></li><li id="cite_note-AdisInternational1993-45"> <span id="mw-reference-text-cite_note-AdisInternational1993-45" class="mw-reference-text"><cite class="citation book cs1"><a href="javascript:if(confirm('https://books.google.com/books?id=roFNAQAAIAAJ  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=roFNAQAAIAAJ'" tppabs="https://books.google.com/books?id=roFNAQAAIAAJ" class="external text external"><i>Drugs &amp; Aging</i></a>. Adis International. 1993. <q>In 16 male subjects undergoing androgen blockade with nilutamide 100 to 300 mg/day for 8 weeks for male to female gender reassignment, prostate volume was not changed (de Voogt et al. 1987).</q></cite></span></li><li id="cite_note-Meyers2018-46"> <span id="mw-reference-text-cite_note-Meyers2018-46" class="mw-reference-text"><cite id="CITEREFRobert_A._Meyers2018" class="citation book cs1">Robert A. Meyers (2 March 2018). <a href="javascript:if(confirm('https://books.google.com/books?id=kuhPDwAAQBAJ&pg=PA46  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=kuhPDwAAQBAJ&pg=PA46'" tppabs="https://books.google.com/books?id=kuhPDwAAQBAJ&pg=PA46" class="external text external"><i>Translational Medicine: Molecular Pharmacology and Drug Discovery</i></a>. Wiley. pp.<span>&nbsp;</span>46–. ISBN<span>&nbsp;</span><bdi>978-3-527-68719-0</bdi>.</cite></span></li><li id="cite_note-Bautista-VidalBarnoiu2014-47"> <span id="mw-reference-text-cite_note-Bautista-VidalBarnoiu2014-47" class="mw-reference-text"><cite id="CITEREFBautista-VidalBarnoiuGarcía-GalisteoGómez-Lechuga2014" class="citation journal cs1">Bautista-Vidal, C.; Barnoiu, O.; García-Galisteo, E.; Gómez-Lechuga, P.; Baena-González, V. (2014). "Treatment of gynecomastia in patients with prostate cancer and androgen deprivation". <i>Actas Urológicas Españolas (English Edition)</i>. <b>38</b> (1): 34–40. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2Fj.acuroe.2013.10.002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2Fj.acuroe.2013.10.002'" tppabs="https://doi.org/10.1016%2Fj.acuroe.2013.10.002" class="external text external">10.1016/j.acuroe.2013.10.002</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/2173-5786  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/2173-5786'" tppabs="https://www.worldcat.org/issn/2173-5786" class="external text external">2173-5786</a>. <q>[...] the frequency of gynecomastia with antiandrogens in monotherapy is [...] around [...] 79% with nilutamide [...]</q></cite></span></li><li id="cite_note-DeepinderBraunstein2012-48"> <span id="mw-reference-text-cite_note-DeepinderBraunstein2012-48" class="mw-reference-text"><cite id="CITEREFDeepinderBraunstein2012" class="citation journal cs1">Deepinder, Fnu; Braunstein, Glenn D (2012). "Drug-induced gynecomastia: an evidence-based review". <i>Expert Opinion on Drug Safety</i>. <b>11</b> (5): 779–795. doi:<a href="javascript:if(confirm('https://doi.org/10.1517%2F14740338.2012.712109  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1517%2F14740338.2012.712109'" tppabs="https://doi.org/10.1517%2F14740338.2012.712109" class="external text external">10.1517/14740338.2012.712109</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1474-0338  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1474-0338'" tppabs="https://www.worldcat.org/issn/1474-0338" class="external text external">1474-0338</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22862307  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22862307'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22862307" class="external text external">22862307</a>. <q>Treatment with estrogen has the highest incidence of gynecomastia, at 40 – 80%, anti-androgens, including flutamide, bicalutamide and nilutamide, are next, with a 40 – 70% incidence, followed by GnRH analogs (goserelin, leuprorelin) and combined androgen deprivation [...]</q></cite></span></li><li id="cite_note-MichalopoulosKeshtgar2012-49"> <span id="mw-reference-text-cite_note-MichalopoulosKeshtgar2012-49" class="mw-reference-text"><cite id="CITEREFMichalopoulosKeshtgar2012" class="citation journal cs1">Michalopoulos, Nikolaos V.; Keshtgar, Mohammed R. (2012). "Gynecomastia Induced by Prostate-Cancer Treatment". <i>New England Journal of Medicine</i>. <b>367</b> (15): 1449. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMicm1209166  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMicm1209166'" tppabs="https://doi.org/10.1056%2FNEJMicm1209166" class="external text external">10.1056/NEJMicm1209166</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0028-4793  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0028-4793'" tppabs="https://www.worldcat.org/issn/0028-4793" class="external text external">0028-4793</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23050528  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23050528'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23050528" class="external text external">23050528</a>. <q>Gynecomastia occurs in up to 80% of patients who receive nonsteroidal antiandrogens (eg, bicalutamide, flutamide, or nilutamide), usually within the first 6 to 9 months after the initiation of treatment.</q></cite></span></li><li id="cite_note-pmid16321765-50"> <span id="mw-reference-text-cite_note-pmid16321765-50" class="mw-reference-text"><cite id="CITEREFDi_LorenzoAutorinoPerdonàDe_Placido2005" class="citation journal cs1">Di Lorenzo G, Autorino R, Perdonà S, De Placido S (December 2005). "Management of gynaecomastia in patients with prostate cancer: a systematic review". <i>Lancet Oncol</i>. <b>6</b> (12): 972–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS1470-2045%2805%2970464-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS1470-2045%2805%2970464-2'" tppabs="https://doi.org/10.1016%2FS1470-2045%2805%2970464-2" class="external text external">10.1016/S1470-2045(05)70464-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16321765  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16321765'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16321765" class="external text external">16321765</a>.</cite></span></li><li id="cite_note-CamusIII2010-51"> <span id="mw-reference-text-cite_note-CamusIII2010-51" class="mw-reference-text"><cite id="CITEREFPhillipe_CamusEdward_C_Rosenow_III2010" class="citation book cs1">Phillipe Camus; Edward C Rosenow III (29 October 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=QlJsBgAAQBAJ&pg=PA235  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=QlJsBgAAQBAJ&pg=PA235'" tppabs="https://books.google.com/books?id=QlJsBgAAQBAJ&pg=PA235" class="external text external"><i>Drug-induced and Iatrogenic Respiratory Disease</i></a>. CRC Press. pp.<span>&nbsp;</span>235–. ISBN<span>&nbsp;</span><bdi>978-1-4441-2869-7</bdi>.</cite></span></li><li id="cite_note-Held-Warmkessel2006-52"> <span id="mw-reference-text-cite_note-Held-Warmkessel2006-52" class="mw-reference-text"><cite id="CITEREFJeanne_Held-Warmkessel2006" class="citation book cs1">Jeanne Held-Warmkessel (2006). <a href="javascript:if(confirm('https://books.google.com/books?id=dZe4ZSVDdBsC&pg=PA257  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=dZe4ZSVDdBsC&pg=PA257'" tppabs="https://books.google.com/books?id=dZe4ZSVDdBsC&pg=PA257" class="external text external"><i>Contemporary Issues in Prostate Cancer: A Nursing Perspective</i></a>. Jones &amp; Bartlett Learning. pp.<span>&nbsp;</span>257–. ISBN<span>&nbsp;</span><bdi>978-0-7637-3075-8</bdi>.</cite></span></li><li id="cite_note-RamonDenis2007-53"> <span id="mw-reference-text-cite_note-RamonDenis2007-53" class="mw-reference-text"><cite id="CITEREFJ._RamonL.J._Denis2007" class="citation book cs1">J. Ramon; L.J. Denis (5 June 2007). <a href="javascript:if(confirm('https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA229  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA229'" tppabs="https://books.google.com/books?id=Bg6ZbqhhboUC&pg=PA229" class="external text external"><i>Prostate Cancer</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>229–. ISBN<span>&nbsp;</span><bdi>978-3-540-40901-4</bdi>.</cite></span></li><li id="cite_note-Mahler1996-54"> <span id="mw-reference-text-cite_note-Mahler1996-54" class="mw-reference-text"><cite id="CITEREFMahler1996" class="citation book cs1">Mahler, Charles (1996). "A Review of the Clinical Studies with Nilutamide". <i>Antiandrogens in Prostate Cancer</i>. pp.<span>&nbsp;</span>105–111. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-642-45745-6_10  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-642-45745-6_10'" tppabs="https://doi.org/10.1007%2F978-3-642-45745-6_10" class="external text external">10.1007/978-3-642-45745-6_10</a>. ISBN<span>&nbsp;</span><bdi>978-3-642-45747-0</bdi>. <q>Akaza had to prematurely terminate a nilutamide study in Japan as 12.6% of his patients developed interstitial lung disease [4]. This complication has been mainly observed in Japan and much less in other trials worldwide.</q></cite></span></li><li id="cite_note-Micromedex2003-55"> <span id="mw-reference-text-cite_note-Micromedex2003-55" class="mw-reference-text"><cite id="CITEREFMicromedex2003" class="citation book cs1">Micromedex (1 January 2003). <a href="javascript:if(confirm('https://books.google.com/books?id=zEzWtsVl-KgC  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=zEzWtsVl-KgC'" tppabs="https://books.google.com/books?id=zEzWtsVl-KgC" class="external text external"><i>USP DI 2003: Drug Information for Healthcare Professionals</i></a>. Thomson Micromedex. pp.<span>&nbsp;</span>220–224. ISBN<span>&nbsp;</span><bdi>978-1-56363-429-1</bdi>.</cite></span></li><li id="cite_note-pmid1580304-56"> <span id="mw-reference-text-cite_note-pmid1580304-56" class="mw-reference-text"><cite id="CITEREFGomezDupontCusanTremblay1992" class="citation journal cs1">Gomez JL, Dupont A, Cusan L, Tremblay M, Tremblay M, Labrie F (1992). "Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report". <i>Am. J. Med</i>. <b>92</b> (5): 563–6. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0002-9343%2892%2990756-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0002-9343%2892%2990756-2'" tppabs="https://doi.org/10.1016%2F0002-9343%2892%2990756-2" class="external text external">10.1016/0002-9343(92)90756-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1580304  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1580304'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1580304" class="external text external">1580304</a>.</cite></span></li><li id="cite_note-Aronson2009-57"> <span id="mw-reference-text-cite_note-Aronson2009-57" class="mw-reference-text"><cite id="CITEREFJeffrey_K._Aronson2009" class="citation book cs1">Jeffrey K. Aronson (21 February 2009). <a href="javascript:if(confirm('https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA150  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA150'" tppabs="https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA150" class="external text external"><i>Meyler's Side Effects of Endocrine and Metabolic Drugs</i></a>. Elsevier. pp.<span>&nbsp;</span>150–. ISBN<span>&nbsp;</span><bdi>978-0-08-093292-7</bdi>.</cite></span></li><li id="cite_note-pmid10388026-58"> <span id="mw-reference-text-cite_note-pmid10388026-58" class="mw-reference-text"><cite id="CITEREFMcLeod1997" class="citation journal cs1">McLeod DG (1997). <a href="javascript:if(confirm('https://doi.org/10.1634/theoncologist.2-1-18  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1634/theoncologist.2-1-18'" tppabs="https://doi.org/10.1634/theoncologist.2-1-18" class="external text external">"Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer"</a>. <i>Oncologist</i>. <b>2</b> (1): 18–27. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1634%2Ftheoncologist.2-1-18  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1634%2Ftheoncologist.2-1-18'" tppabs="https://doi.org/10.1634%2Ftheoncologist.2-1-18" class="external text external">10.1634/theoncologist.2-1-18</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/10388026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/10388026'" tppabs="https://pubmed.ncbi.nlm.nih.gov/10388026" class="external text external">10388026</a>. <q>Incidences of abnormal liver function test results have been variously reported from 2%-33% in nilutamide groups [13, 32, 33, 45] and from 4%-62% in flutamide groups [5, 7, 9, 11, 34, 38-40, 48] in trials of monotherapy and CAB.</q></cite></span></li><li id="cite_note-Aronson2011-59"> <span id="mw-reference-text-cite_note-Aronson2011-59" class="mw-reference-text"><cite id="CITEREFJ._K._Aronson2011" class="citation book cs1">J. K. Aronson (2011). <a href="javascript:if(confirm('https://books.google.com/books?id=zegpAgEt3CcC&pg=PA874  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=zegpAgEt3CcC&pg=PA874'" tppabs="https://books.google.com/books?id=zegpAgEt3CcC&pg=PA874" class="external text external"><i>Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions</i></a>. Elsevier. pp.<span>&nbsp;</span>874–. ISBN<span>&nbsp;</span><bdi>978-0-444-53741-6</bdi>.</cite></span></li><li id="cite_note-pmid8977826-60"> <span id="mw-reference-text-cite_note-pmid8977826-60" class="mw-reference-text"><cite id="CITEREFMartyGodartDoermannMérillon1996" class="citation journal cs1">Marty F, Godart D, Doermann F, Mérillon H (1996). "[Fatal fulminating hepatitis caused by nilutamide. A new case]". <i>Gastroenterol. Clin. Biol.</i> (in French). <b>20</b> (8–9): 710–1. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8977826  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8977826'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8977826" class="external text external">8977826</a>.</cite></span></li><li id="cite_note-MerwatKabbani2008-61"> <span id="mw-reference-text-cite_note-MerwatKabbani2008-61" class="mw-reference-text"><cite id="CITEREFMerwatKabbaniAdler2008" class="citation journal cs1">Merwat, Shehzad N.; Kabbani, Wareef; Adler, Douglas G. (2008). "Fulminant Hepatic Failure due to Nilutamide Hepatotoxicity". <i>Digestive Diseases and Sciences</i>. <b>54</b> (4): 910–913. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs10620-008-0406-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs10620-008-0406-8'" tppabs="https://doi.org/10.1007%2Fs10620-008-0406-8" class="external text external">10.1007/s10620-008-0406-8</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0163-2116  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0163-2116'" tppabs="https://www.worldcat.org/issn/0163-2116" class="external text external">0163-2116</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18688719  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18688719'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18688719" class="external text external">18688719</a>. <q>In addition, nilutamide is noted to exhibit mitochondrial toxicity by inhibiting complex I activity of the mitochondrial respiratory chain leading to the impairment of ATP formation and the biosynthesis of glutathione, thereby possibly predisposing the liver to toxicity [13].</q></cite></span></li><li id="cite_note-ChitturiFarrell2013-62"> <span id="mw-reference-text-cite_note-ChitturiFarrell2013-62" class="mw-reference-text"><cite id="CITEREFChitturiFarrell2013" class="citation book cs1">Chitturi, Shivakumar; Farrell, Geoffrey C (2013). "Adverse Effects of Hormones and Hormone Antagonists on the Liver". <i>Drug-Induced Liver Disease</i>. pp.<span>&nbsp;</span>605–619. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FB978-0-12-387817-5.00033-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FB978-0-12-387817-5.00033-9'" tppabs="https://doi.org/10.1016%2FB978-0-12-387817-5.00033-9" class="external text external">10.1016/B978-0-12-387817-5.00033-9</a>. ISBN<span>&nbsp;</span><bdi>9780123878175</bdi>. <q>Liver injury is well recognized with all antiandrogens (Table 33-3). Thus, among all published cases identified between 1986 and 2003, flutamide (46), cyproterone (21), nilutamide (4), and bicalutamide (1) were implicated [107,108].</q></cite></span></li><li id="cite_note-pmid8035313-63"> <span id="mw-reference-text-cite_note-pmid8035313-63" class="mw-reference-text"><cite id="CITEREFBersonSchmetsFischFau1994" class="citation journal cs1">Berson A, Schmets L, Fisch C, Fau D, Wolf C, Fromenty B, Deschamps D, Pessayre D (1994). "Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen". <i>J. Pharmacol. Exp. Ther</i>. <b>270</b> (1): 167–76. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8035313  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8035313'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8035313" class="external text external">8035313</a>.</cite></span></li><li id="cite_note-CoeJia2007-64"> <span id="mw-reference-text-cite_note-CoeJia2007-64" class="mw-reference-text"><cite id="CITEREFCoeJiaHoRademacher2007" class="citation journal cs1">Coe, Kevin J.; Jia, Yankai; Ho, Han Kiat; Rademacher, Peter; Bammler, Theo K.; Beyer, Richard P.; Farin, Frederico M.; Woodke, Libby; Plymate, Stephen R.; Fausto, Nelson; Nelson, Sidney D. (2007). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183" class="external text external">"Comparison of the Cytotoxicity of the Nitroaromatic Drug Flutamide to Its Cyano Analogue in the Hepatocyte Cell Line TAMH: Evidence for Complex I Inhibition and Mitochondrial Dysfunction Using Toxicogenomic Screening"</a>. <i>Chemical Research in Toxicology</i>. <b>20</b> (9): 1277–1290. doi:<a href="javascript:if(confirm('https://doi.org/10.1021%2Ftx7001349  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1021%2Ftx7001349'" tppabs="https://doi.org/10.1021%2Ftx7001349" class="external text external">10.1021/tx7001349</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0893-228X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0893-228X'" tppabs="https://www.worldcat.org/issn/0893-228X" class="external text external">0893-228X</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802183" class="external text external">2802183</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17702527  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17702527'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17702527" class="external text external">17702527</a>.</cite></span></li><li id="cite_note-BoelsterliHo2006-65"> <span id="mw-reference-text-cite_note-BoelsterliHo2006-65" class="mw-reference-text"><cite id="CITEREFBoelsterliHoZhouYeow_Leow2006" class="citation journal cs1">Boelsterli, Urs; Ho, Han; Zhou, Shufeng; Yeow Leow, Koon (2006). "Bioactivation and Hepatotoxicity of Nitroaromatic Drugs". <i>Current Drug Metabolism</i>. <b>7</b> (7): 715–727. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F138920006778520606  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F138920006778520606'" tppabs="https://doi.org/10.2174%2F138920006778520606" class="external text external">10.2174/138920006778520606</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1389-2002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1389-2002'" tppabs="https://www.worldcat.org/issn/1389-2002" class="external text external">1389-2002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17073576  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17073576'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17073576" class="external text external">17073576</a>.</cite></span></li><li id="cite_note-Gaillard1996-66"> <span id="mw-reference-text-cite_note-Gaillard1996-66" class="mw-reference-text"><cite id="CITEREFGaillard1996" class="citation book cs1">Gaillard, Martine (1996). "Pharmacodynamics and Pharmacokinetics of Nilutamide in Animal and Man". <i>Antiandrogens in Prostate Cancer</i>. pp.<span>&nbsp;</span>95–103. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2F978-3-642-45745-6_9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2F978-3-642-45745-6_9'" tppabs="https://doi.org/10.1007%2F978-3-642-45745-6_9" class="external text external">10.1007/978-3-642-45745-6_9</a>. ISBN<span>&nbsp;</span><bdi>978-3-642-45747-0</bdi>.</cite></span></li><li id="cite_note-FiggChau2010-67"> <span id="mw-reference-text-cite_note-FiggChau2010-67" class="mw-reference-text"><cite id="CITEREFWilliam_FiggCindy_H._ChauEric_J._Small2010" class="citation book cs1">William Figg; Cindy H. Chau; Eric J. Small (14 September 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA71  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA71'" tppabs="https://books.google.com/books?id=4KDrjeWA5-UC&pg=PA71" class="external text external"><i>Drug Management of Prostate Cancer</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>71–. ISBN<span>&nbsp;</span><bdi>978-1-60327-829-4</bdi>.</cite></span></li><li id="cite_note-BenniVemer1990-68"> <span id="mw-reference-text-cite_note-BenniVemer1990-68" class="mw-reference-text"><cite id="CITEREFH.J.T._Coelingh_BenniH.M._Vemer1990" class="citation book cs1">H.J.T. Coelingh Benni; H.M. Vemer (15 December 1990). <a href="javascript:if(confirm('https://books.google.com/books?id=q6zqFrCLUoIC&pg=PA153  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=q6zqFrCLUoIC&pg=PA153'" tppabs="https://books.google.com/books?id=q6zqFrCLUoIC&pg=PA153" class="external text external"><i>Chronic Hyperandrogenic Anovulation</i></a>. CRC Press. pp.<span>&nbsp;</span>153–. ISBN<span>&nbsp;</span><bdi>978-1-85070-322-8</bdi>.</cite></span></li><li id="cite_note-pmid3331376-69"> <span id="mw-reference-text-cite_note-pmid3331376-69" class="mw-reference-text"><cite id="CITEREFRaynaudFietLe_GoffMartin1987" class="citation journal cs1">Raynaud JP, Fiet J, Le Goff JM, Martin PM, Moguilewsky M, Ojasoo T (1987). "Design of antiandrogens and their mechanisms of action: a case study (anandron)". <i>Horm. Res</i>. <b>28</b> (2–4): 230–41. doi:<a href="javascript:if(confirm('https://doi.org/10.1159%2F000180948  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1159%2F000180948'" tppabs="https://doi.org/10.1159%2F000180948" class="external text external">10.1159/000180948</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3331376  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3331376'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3331376" class="external text external">3331376</a>.</cite></span></li><li id="cite_note-RaynaudBonne1979-70"> <span id="mw-reference-text-cite_note-RaynaudBonne1979-70" class="mw-reference-text"><cite class="citation journal cs1">Raynaud, Jean-Pierre; Bonne, Claude; Bouton, Marie-Madeleine; Lagace, Lisette; Labrie, Fernand (1979). "Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues". <i>Journal of Steroid Biochemistry</i>. <b>11</b> (1): 93–99. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2879%2990281-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2879%2990281-4'" tppabs="https://doi.org/10.1016%2F0022-4731%2879%2990281-4" class="external text external">10.1016/0022-4731(79)90281-4</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0022-4731  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0022-4731'" tppabs="https://www.worldcat.org/issn/0022-4731" class="external text external">0022-4731</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/385986  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/385986'" tppabs="https://pubmed.ncbi.nlm.nih.gov/385986" class="external text external">385986</a>.</cite></span></li><li id="cite_note-pmid3625091-71"> <span id="mw-reference-text-cite_note-pmid3625091-71" class="mw-reference-text"><cite id="CITEREFFurrValcacciaCurryWoodburn1987" class="citation journal cs1">Furr BJ, Valcaccia B, Curry B, Woodburn JR, Chesterson G, Tucker H (June 1987). "ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen". <i>J. Endocrinol</i>. <b>113</b> (3): R7–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1677%2Fjoe.0.113R007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1677%2Fjoe.0.113R007'" tppabs="https://doi.org/10.1677%2Fjoe.0.113R007" class="external text external">10.1677/joe.0.113R007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3625091  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3625091'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3625091" class="external text external">3625091</a>.</cite></span></li><li id="cite_note-pmid8136296Receptor-72"> <span id="mw-reference-text-cite_note-pmid8136296Receptor-72" class="mw-reference-text"><cite id="CITEREFTeutschGoubetBattmannBonfils1994" class="citation journal cs1">Teutsch G, Goubet F, Battmann T, Bonfils A, Bouchoux F, Cerede E, Gofflo D, Gaillard-Kelly M, Philibert D (January 1994). "Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgen receptor". <i>J. Steroid Biochem. Mol. Biol</i>. <b>48</b> (1): 111–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0960-0760%2894%2990257-7  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0960-0760%2894%2990257-7'" tppabs="https://doi.org/10.1016%2F0960-0760%2894%2990257-7" class="external text external">10.1016/0960-0760(94)90257-7</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8136296  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8136296'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8136296" class="external text external">8136296</a>.</cite></span></li><li id="cite_note-pmid2615358-73"> <span id="mw-reference-text-cite_note-pmid2615358-73" class="mw-reference-text"><cite id="CITEREFWinnekerWagnerBatzold1989" class="citation journal cs1">Winneker RC, Wagner MM, Batzold FH (December 1989). "Studies on the mechanism of action of Win 49596: a steroidal androgen receptor antagonist". <i>J. Steroid Biochem</i>. <b>33</b> (6): 1133–8. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2889%2990420-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2889%2990420-2'" tppabs="https://doi.org/10.1016%2F0022-4731%2889%2990420-2" class="external text external">10.1016/0022-4731(89)90420-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2615358  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2615358'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2615358" class="external text external">2615358</a>.</cite></span></li><li id="cite_note-LuoMartel1996-74"> <span id="mw-reference-text-cite_note-LuoMartel1996-74" class="mw-reference-text"><cite id="CITEREFLuoMartelLeBlancCandas1996" class="citation journal cs1">Luo, S; Martel, C; LeBlanc, G; Candas, B; Singh, S M; Labrie, C; Simard, J; Belanger, A; Labrie, F (1996). "Relative potencies of Flutamide and Casodex: preclinical studies". <i>Endocrine Related Cancer</i>. <b>3</b> (3): 229–241. doi:<a href="javascript:if(confirm('https://doi.org/10.1677%2Ferc.0.0030229  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1677%2Ferc.0.0030229'" tppabs="https://doi.org/10.1677%2Ferc.0.0030229" class="external text external">10.1677/erc.0.0030229</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1351-0088  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1351-0088'" tppabs="https://www.worldcat.org/issn/1351-0088" class="external text external">1351-0088</a>.</cite></span></li><li id="cite_note-pmid2788775-75"> <span id="mw-reference-text-cite_note-pmid2788775-75" class="mw-reference-text"><cite id="CITEREFAyubLevell1989" class="citation journal cs1">Ayub M, Levell MJ (August 1989). "The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins". <i>J. Steroid Biochem</i>. <b>33</b> (2): 251–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2889%2990301-4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2889%2990301-4'" tppabs="https://doi.org/10.1016%2F0022-4731%2889%2990301-4" class="external text external">10.1016/0022-4731(89)90301-4</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2788775  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2788775'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2788775" class="external text external">2788775</a>.</cite></span></li><li id="cite_note-pmid8693644-76"> <span id="mw-reference-text-cite_note-pmid8693644-76" class="mw-reference-text"><cite id="CITEREFKemppainenWilson1996" class="citation journal cs1">Kemppainen JA, Wilson EM (July 1996). "Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization". <i>Urology</i>. <b>48</b> (1): 157–63. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2FS0090-4295%2896%2900117-3  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2FS0090-4295%2896%2900117-3'" tppabs="https://doi.org/10.1016%2FS0090-4295%2896%2900117-3" class="external text external">10.1016/S0090-4295(96)00117-3</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8693644  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8693644'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8693644" class="external text external">8693644</a>.</cite></span></li><li id="cite_note-FerrandoLevenson2010-77"> <span id="mw-reference-text-cite_note-FerrandoLevenson2010-77" class="mw-reference-text"><cite id="CITEREFStephen_J._FerrandoJames_L._LevensonJames_A._Owen2010" class="citation book cs1">Stephen J. Ferrando; James L. Levenson; James A. Owen (20 May 2010). <a href="javascript:if(confirm('https://books.google.com/books?id=9b5NkWZ5k8wC&pg=PA256  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=9b5NkWZ5k8wC&pg=PA256'" tppabs="https://books.google.com/books?id=9b5NkWZ5k8wC&pg=PA256" class="external text external"><i>Clinical Manual of Psychopharmacology in the Medically Ill</i></a>. American Psychiatric Pub. pp.<span>&nbsp;</span>256–. ISBN<span>&nbsp;</span><bdi>978-1-58562-942-8</bdi>.</cite></span></li><li id="cite_note-HarrisColeman1993-78"> <span id="mw-reference-text-cite_note-HarrisColeman1993-78" class="mw-reference-text"><cite id="CITEREFHarrisColemanFauldsChrisp1993" class="citation journal cs1">Harris, Martin G.; Coleman, Stephen G.; Faulds, Diana; Chrisp, Paul (1993). "Nilutamide". <i>Drugs &amp; Aging</i>. <b>3</b> (1): 9–25. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00002512-199303010-00002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00002512-199303010-00002'" tppabs="https://doi.org/10.2165%2F00002512-199303010-00002" class="external text external">10.2165/00002512-199303010-00002</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/1170-229X  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/1170-229X'" tppabs="https://www.worldcat.org/issn/1170-229X" class="external text external">1170-229X</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8453188  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8453188'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8453188" class="external text external">8453188</a>.</cite></span></li><li id="cite_note-pmid2956461-79"> <span id="mw-reference-text-cite_note-pmid2956461-79" class="mw-reference-text"><cite id="CITEREFAyubLevell1987" class="citation journal cs1">Ayub M, Levell MJ (1987). "Inhibition of rat testicular 17 alpha-hydroxylase and 17,20-lyase activities by anti-androgens (flutamide, hydroxyflutamide, RU23908, cyproterone acetate) in vitro". <i>J. Steroid Biochem</i>. <b>28</b> (1): 43–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2887%2990122-1  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2887%2990122-1'" tppabs="https://doi.org/10.1016%2F0022-4731%2887%2990122-1" class="external text external">10.1016/0022-4731(87)90122-1</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/2956461  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/2956461'" tppabs="https://pubmed.ncbi.nlm.nih.gov/2956461" class="external text external">2956461</a>.</cite></span></li><li id="cite_note-Denis2012b-80"> <span id="mw-reference-text-cite_note-Denis2012b-80" class="mw-reference-text"><cite class="citation book cs1">Louis Denis (6 December 2012). <a href="javascript:if(confirm('https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT202  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT202'" tppabs="https://books.google.com/books?id=jqZDBQAAQBAJ&pg=PT202" class="external text external"><i>Antiandrogens in Prostate Cancer: A Key to Tailored Endocrine Treatment</i></a>. Springer Science &amp; Business Media. pp.<span>&nbsp;</span>202–. ISBN<span>&nbsp;</span><bdi>978-3-642-45745-6</bdi>. <q>The plateau level of nilutamide (steady state) was obtained after about 14 days of repeated administration of the drug (150 mg b.i.d.) and did not depend upon intervals between doses.</q></cite></span></li><li id="cite_note-MahlerVerhelst1998-81"> <span id="mw-reference-text-cite_note-MahlerVerhelst1998-81" class="mw-reference-text"><cite id="CITEREFMahlerVerhelstDenis1998" class="citation journal cs1">Mahler, Ch; Verhelst, J; Denis, L (1998). "Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer". <i>Clinical Pharmacokinetics</i>. <b>34</b> (5): 405–417. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003088-199834050-00005  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003088-199834050-00005'" tppabs="https://doi.org/10.2165%2F00003088-199834050-00005" class="external text external">10.2165/00003088-199834050-00005</a>. ISSN<span>&nbsp;</span><a href="javascript:if(confirm('https://www.worldcat.org/issn/0312-5963  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.worldcat.org/issn/0312-5963'" tppabs="https://www.worldcat.org/issn/0312-5963" class="external text external">0312-5963</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/9592622  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/9592622'" tppabs="https://pubmed.ncbi.nlm.nih.gov/9592622" class="external text external">9592622</a>.</cite></span></li><li id="cite_note-FischerKlein2018-82"> <span id="mw-reference-text-cite_note-FischerKlein2018-82" class="mw-reference-text"><cite id="CITEREFJános_FischerChristian_KleinWayne_E._Childers2018" class="citation book cs1">János Fischer; Christian Klein; Wayne E. Childers (16 April 2018). <a href="javascript:if(confirm('https://books.google.com/books?id=t-JVDwAAQBAJ&pg=PA98  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.com/books?id=t-JVDwAAQBAJ&pg=PA98'" tppabs="https://books.google.com/books?id=t-JVDwAAQBAJ&pg=PA98" class="external text external"><i>Successful Drug Discovery</i></a>. Wiley. pp.<span>&nbsp;</span>98–. ISBN<span>&nbsp;</span><bdi>978-3-527-80868-7</bdi>.</cite></span></li><li id="cite_note-83"> <span id="mw-reference-text-cite_note-83" class="mw-reference-text"><cite id="CITEREFWellingtonKeam2006" class="citation journal cs1">Wellington K, Keam SJ (2006). "Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer". <i>Drugs</i>. <b>66</b> (6): 837–50. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00003495-200666060-00007  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00003495-200666060-00007'" tppabs="https://doi.org/10.2165%2F00003495-200666060-00007" class="external text external">10.2165/00003495-200666060-00007</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16706554  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16706554'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16706554" class="external text external">16706554</a>.</cite></span></li><li id="cite_note-pmid3420036-84"> <span id="mw-reference-text-cite_note-pmid3420036-84" class="mw-reference-text"><cite id="CITEREFRaoGeldofvan_der_Wiltde_Voogt1988" class="citation journal cs1">Rao BR, Geldof AA, van der Wilt CL, de Voogt HJ (1988). "Efficacy and advantages in the use of low doses of Anandron and estrogen combination in the treatment of prostate cancer". <i>Prostate</i>. <b>13</b> (1): 69–78. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fpros.2990130108  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fpros.2990130108'" tppabs="https://doi.org/10.1002%2Fpros.2990130108" class="external text external">10.1002/pros.2990130108</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3420036  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3420036'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3420036" class="external text external">3420036</a>.</cite></span></li><li id="cite_note-pmid25665553-85"> <span id="mw-reference-text-cite_note-pmid25665553-85" class="mw-reference-text"><cite id="CITEREFChiaO'BrienBrownLim2015" class="citation journal cs1">Chia K, O'Brien M, Brown M, Lim E (February 2015). "Targeting the androgen receptor in breast cancer". <i>Curr Oncol Rep</i>. <b>17</b> (2): 4. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs11912-014-0427-8  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs11912-014-0427-8'" tppabs="https://doi.org/10.1007%2Fs11912-014-0427-8" class="external text external">10.1007/s11912-014-0427-8</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25665553  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25665553'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25665553" class="external text external">25665553</a>.</cite></span></li><li id="cite_note-pmid1903951-86"> <span id="mw-reference-text-cite_note-pmid1903951-86" class="mw-reference-text"><cite id="CITEREFMillwardCantwellDowsettCarmichael1991" class="citation journal cs1">Millward MJ, Cantwell BM, Dowsett M, Carmichael J, Harris AL (May 1991). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972372  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972372'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972372" class="external text external">"Phase II clinical and endocrine study of Anandron (RU-23908) in advanced post-menopausal breast cancer"</a>. <i>Br. J. Cancer</i>. <b>63</b> (5): 763–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1038%2Fbjc.1991.170  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1038%2Fbjc.1991.170'" tppabs="https://doi.org/10.1038%2Fbjc.1991.170" class="external text external">10.1038/bjc.1991.170</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972372  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972372'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972372" class="external text external">1972372</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1903951  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1903951'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1903951" class="external text external">1903951</a>.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Further_reading">Further reading</h2></summary>
    
<ul><li><cite id="CITEREFRaynaudBonneMoguilewskyLefebvre1984" class="citation journal cs1">Raynaud JP, Bonne C, Moguilewsky M, Lefebvre FA, Bélanger A, Labrie F (1984). "The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review". <i>Prostate</i>. <b>5</b> (3): 299–311. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fpros.2990050307  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fpros.2990050307'" tppabs="https://doi.org/10.1002%2Fpros.2990050307" class="external text external">10.1002/pros.2990050307</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/6374639  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/6374639'" tppabs="https://pubmed.ncbi.nlm.nih.gov/6374639" class="external text external">6374639</a>.</cite></li>
<li><cite id="CITEREFMoguilewskyBertagnaHucher1987" class="citation journal cs1">Moguilewsky M, Bertagna C, Hucher M (1987). "Pharmacological and clinical studies of the antiandrogen Anandron". <i>J. Steroid Biochem</i>. <b>27</b> (4–6): 871–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0022-4731%2887%2990162-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0022-4731%2887%2990162-2'" tppabs="https://doi.org/10.1016%2F0022-4731%2887%2990162-2" class="external text external">10.1016/0022-4731(87)90162-2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3320565  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3320565'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3320565" class="external text external">3320565</a>.</cite></li>
<li><cite id="CITEREFDu_Plessis1991" class="citation journal cs1">Du Plessis DJ (1991). "Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review". <i>Urology</i>. <b>37</b> (2 Suppl): 20–4. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0090-4295%2891%2980097-q  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0090-4295%2891%2980097-q'" tppabs="https://doi.org/10.1016%2F0090-4295%2891%2980097-q" class="external text external">10.1016/0090-4295(91)80097-q</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1992599  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1992599'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1992599" class="external text external">1992599</a>.</cite></li>
<li><cite id="CITEREFCreavenPendyalaTremblay1991" class="citation journal cs1">Creaven PJ, Pendyala L, Tremblay D (1991). "Pharmacokinetics and metabolism of nilutamide". <i>Urology</i>. <b>37</b> (2 Suppl): 13–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1016%2F0090-4295%2891%2980096-p  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1016%2F0090-4295%2891%2980096-p'" tppabs="https://doi.org/10.1016%2F0090-4295%2891%2980096-p" class="external text external">10.1016/0090-4295(91)80096-p</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/1992598  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/1992598'" tppabs="https://pubmed.ncbi.nlm.nih.gov/1992598" class="external text external">1992598</a>.</cite></li>
<li><cite class="citation journal cs1">Harris MG, Coleman SG, Faulds D, Chrisp P (1993). "Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer". <i>Drugs Aging</i>. <b>3</b> (1): 9–25. doi:<a href="javascript:if(confirm('https://doi.org/10.2165%2F00002512-199303010-00002  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2165%2F00002512-199303010-00002'" tppabs="https://doi.org/10.2165%2F00002512-199303010-00002" class="external text external">10.2165/00002512-199303010-00002</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8453188  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8453188'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8453188" class="external text external">8453188</a>.</cite></li>
<li><cite class="citation journal cs1">Dole EJ, Holdsworth MT (1997). "Nilutamide: an antiandrogen for the treatment of prostate cancer". <i>Ann Pharmacother</i>. <b>31</b> (1): 65–75. doi:<a href="javascript:if(confirm('https://doi.org/10.1177%2F106002809703100112  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F106002809703100112'" tppabs="https://doi.org/10.1177%2F106002809703100112" class="external text external">10.1177/106002809703100112</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/8997470  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/8997470'" tppabs="https://pubmed.ncbi.nlm.nih.gov/8997470" class="external text external">8997470</a>.</cite></li>
<li><cite id="CITEREFIversenMelezinekSchmidt2001" class="citation journal cs1">Iversen P, Melezinek I, Schmidt A (2001). "Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function". <i>BJU Int</i>. <b>87</b> (1): 47–56. doi:<a href="javascript:if(confirm('https://doi.org/10.1046%2Fj.1464-410x.2001.00988.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1046%2Fj.1464-410x.2001.00988.x'" tppabs="https://doi.org/10.1046%2Fj.1464-410x.2001.00988.x" class="external text external">10.1046/j.1464-410x.2001.00988.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11121992  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11121992'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11121992" class="external text external">11121992</a>.</cite></li></ul>
<p>
<br></p>
<div role="navigation" class="navbox" aria-labelledby="Androgens_and_antiandrogens" style="padding:3px"><table class="nowraplinks mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Androgens_and_antiandrogens" style="font-size:114%;margin:0 4em">Androgens and antiandrogens</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Androgens<br>(incl. <abbr>AAS</abbr>)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;"><abbr>AR</abbr> agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Testosterone derivatives:</i> Androstenediol dipropionate</li>
<li>Boldenone undecylenate</li>
<li><a href="Clostebol.htm" tppabs="https://ptable.com/wiki/compounds/A/Clostebol" title="Clostebol">Clostebol</a></li>
<li>Clostebol acetate</li>
<li>Clostebol caproate</li>
<li>Clostebol propionate</li>
<li>Cloxotestosterone acetate</li>
<li>Prasterone (dehydroepiandrosterone, DHEA)</li>
<li>Prasterone enanthate (DHEA enanthate)</li>
<li>Prasterone sulfate (DHEA sulfate)</li>
<li>Quinbolone</li>
<li>Testosterone<sup>#</sup></li>
<li>Testosterone esters (e.g., testosterone cypionate, testosterone enanthate, testosterone propionate, testosterone undecanoate, testosterone ester mixtures (Deposterona, Omnadren, Sustanon, Testoviron Depot))</li></ul>

<ul><li><i>Dihydrotestosterone derivatives:</i> Androstanolone (stanolone, dihydrotestosterone, DHT)</li>
<li>Androstanolone esters</li>
<li>Bolazine capronate</li>
<li>Drostanolone propionate (dromostanolone propionate)</li>
<li>Epitiostanol</li>
<li>Mepitiostane</li>
<li><a href="Mesterolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mesterolone" title="Mesterolone">Mesterolone</a></li>
<li>Metenolone acetate (methenolone acetate)</li>
<li>Metenolone enanthate (methenolone enanthate)</li>
<li>Stenbolone acetate</li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> Bolandiol dipropionate</li>
<li>Nandrolone esters (e.g., nandrolone decanoate, nandrolone phenylpropionate)</li>
<li>Norclostebol</li>
<li>Norclostebol acetate</li>
<li><a href="Oxabolone_cipionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone_cipionate" title="Oxabolone cipionate">Oxabolone cipionate (oxabolone cypionate)</a></li>
<li>Trenbolone acetate</li>
<li>Trenbolone hexahydrobenzylcarbonate (trenbolone cyclohexylmethylcarbonate)</li></ul>

<ul><li><i>17α-Alkylated testosterone derivatives:</i> <a href="Bolasterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bolasterone" title="Bolasterone">Bolasterone</a></li>
<li><a href="Calusterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Calusterone" title="Calusterone">Calusterone</a></li>
<li>Chlorodehydromethyltestosterone (CDMT)</li>
<li><a href="Fluoxymesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoxymesterone" title="Fluoxymesterone">Fluoxymesterone</a></li>
<li><a href="Formebolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Formebolone" title="Formebolone">Formebolone</a></li>
<li>Metandienone (methandienone, methandrostenolone)</li>
<li>Methandriol (methylandrostenediol)</li>
<li>Methandriol bisenanthoyl acetate</li>
<li>Methandriol dipropionate</li>
<li>Methandriol propionate</li>
<li><a href="Methyltestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyltestosterone" title="Methyltestosterone">Methyltestosterone</a></li>
<li>Methyltestosterone 3-hexyl ether</li>
<li>Oxymesterone</li>
<li>Penmesterol</li>
<li>Tiomesterone (thiomesterone)</li></ul>

<ul><li><i>17α-Alkylated dihydrotestosterone derivatives:</i> Androisoxazole</li>
<li><a href="Furazabol.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazabol" title="Furazabol">Furazabol</a></li>
<li>Mebolazine (dimethazine)</li>
<li><a href="Mestanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mestanolone" title="Mestanolone">Mestanolone</a></li>
<li><a href="Oxandrolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxandrolone" title="Oxandrolone">Oxandrolone</a></li>
<li><a href="Oxymetholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxymetholone" title="Oxymetholone">Oxymetholone</a></li>
<li><a href="Stanozolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Stanozolol" title="Stanozolol">Stanozolol</a></li></ul>

<ul><li><i>17α-Alkylated 19-nortestosterone derivatives:</i> <a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol</a></li>
<li>Mibolerone</li>
<li>Norethandrolone</li>
<li>Normethandrone (methylestrenolone, normethisterone)</li>
<li>Propetandrol (propethandrol)</li></ul>

<ul><li><i>17α-Vinyltestosterone derivatives:</i> Norvinisterone (vinylnortestosterone)</li></ul>

<ul><li><i>17α-Ethynyltestosterone derivatives:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li>Progestins (e.g., <a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">ethisterone (ethynyltestosterone)</a>, <a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">levonorgestrel</a>, <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">norgestrel</a>, <a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">norethisterone (norethindrone)</a>, lynestrenol, norgestrienone)</li>
<li>Tibolone</li></ul>

<ul><li><i>Progesterone derivatives:</i> <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Progonadotropins</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Antiestrogens (e.g., <a href="Tamoxifen.htm" tppabs="https://ptable.com/wiki/compounds/A/Tamoxifen" title="Tamoxifen">tamoxifen</a>, <a href="Clomifene.htm" tppabs="https://ptable.com/wiki/compounds/A/Clomifene" title="Clomifene">clomifene</a>)</li>
<li>GnRH agonists (e.g., <a href="Gonadotropin-releasing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gonadotropin-releasing_hormone" title="Gonadotropin-releasing hormone">GnRH (gonadorelin)</a>, <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a>)</li>
<li>Gonadotropins (e.g., <a href="Luteinizing_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Luteinizing_hormone" title="Luteinizing hormone"><abbr>LH</abbr></a>, <a href="Human_chorionic_gonadotropin.htm" tppabs="https://ptable.com/wiki/compounds/A/Human_chorionic_gonadotropin" title="Human chorionic gonadotropin"><abbr>hCG</abbr></a>)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Antiandrogens</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;"><abbr>AR</abbr> antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> Abiraterone acetate</li>
<li>Canrenone</li>
<li>Chlormadinone acetate</li>
<li>Cyproterone acetate</li>
<li>Delmadinone acetate</li>
<li>Dienogest</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>Medrogestone</li>
<li>Megestrol acetate</li>
<li>Nomegestrol acetate</li>
<li>Osaterone acetate</li>
<li>Oxendolone</li>
<li>Potassium canrenoate</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul>

<ul><li><i>Nonsteroidal:</i> Apalutamide</li>
<li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li>Darolutamide</li>
<li>Enzalutamide</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li>Seviteronel<sup>†</sup></li>
<li>Topilutamide (fluridil)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Steroidogenesis<br>inhibitors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">5α-Reductase</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Alfatradiol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Alfatradiol'" tppabs="https://ptable.com/wiki/compounds/A/Alfatradiol" title="Alfatradiol">Alfatradiol</a></li>
<li><a href="Dutasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Dutasteride" title="Dutasteride">Dutasteride</a></li>
<li>Epristeride</li>
<li><a href="Finasteride.htm" tppabs="https://ptable.com/wiki/compounds/A/Finasteride" title="Finasteride">Finasteride</a></li>
<li>Saw palmetto extract</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Abiraterone acetate</li>
<li><a href="Aminoglutethimide.htm" tppabs="https://ptable.com/wiki/compounds/A/Aminoglutethimide" title="Aminoglutethimide">Aminoglutethimide</a></li>
<li>Bifluranol</li>
<li>Cyproterone acetate</li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li>Seviteronel<sup>†</sup></li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Antigonadotropins</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>D<sub>2</sub> receptor antagonists (prolactin releasers) (e.g., <a href="Domperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Domperidone" title="Domperidone">domperidone</a>, <a href="Metoclopramide.htm" tppabs="https://ptable.com/wiki/compounds/A/Metoclopramide" title="Metoclopramide">metoclopramide</a>, <a href="Risperidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Risperidone" title="Risperidone">risperidone</a>, <a href="Haloperidol.htm" tppabs="https://ptable.com/wiki/compounds/A/Haloperidol" title="Haloperidol">haloperidol</a>, <a href="Chlorpromazine.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorpromazine" title="Chlorpromazine">chlorpromazine</a>, <a href="Sulpiride.htm" tppabs="https://ptable.com/wiki/compounds/A/Sulpiride" title="Sulpiride">sulpiride</a>)</li>
<li><a href="Estrogen.htm" tppabs="https://ptable.com/wiki/compounds/A/Estrogen" title="Estrogen">Estrogens</a> (e.g., bifluranol, <a href="Diethylstilbestrol.htm" tppabs="https://ptable.com/wiki/compounds/A/Diethylstilbestrol" title="Diethylstilbestrol">diethylstilbestrol</a>, <a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">estradiol</a>, estradiol esters, ethinylestradiol, ethinylestradiol sulfonate, paroxypropione)</li>
<li>GnRH agonists (e.g., <a href="Leuprorelin.htm" tppabs="https://ptable.com/wiki/compounds/A/Leuprorelin" title="Leuprorelin">leuprorelin</a>)</li>
<li>GnRH antagonists (e.g., <a href="Cetrorelix.htm" tppabs="https://ptable.com/wiki/compounds/A/Cetrorelix" title="Cetrorelix">cetrorelix</a>)</li>
<li>Progestogens (incl., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, <a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">medroxyprogesterone acetate</a>, megestrol acetate)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:9em;;text-align:center;">Others</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Androstenedione immunogens:</i> Androvax (androstenedione albumin)</li>
<li>Ovandrotone albumin (Fecundin)</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td colspan="2" class="navbox-list navbox-even hlist" style="width:100%;padding:0px;background:#DDDDFF;"><div style="padding:0em 0.25em"><div class="hlist">
<ul><li><sup>#</sup>WHO-EM</li>
<li><sup>‡</sup>Withdrawn from market</li>
<li>Clinical trials:
<ul><li><sup>†</sup>Phase III</li>
<li><sup>§</sup>Never to phase III</li></ul></li></ul>
</div>
<dl><dt>See also</dt>
<dd>Androgen receptor modulators</dd>
<dd>Estrogens and antiestrogens</dd>
<dd>Progestogens and antiprogestogens</dd>
<dd>List of androgens/anabolic steroids</dd></dl></div></td></tr></tbody></table></div><span>
</span>
<div role="navigation" class="navbox" aria-labelledby="Androgen_receptor_modulators" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Androgen_receptor_modulators" style="font-size:114%;margin:0 4em">Androgen receptor modulators</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>AR</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Agonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Testosterone derivatives:</i> <a href="4-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenediol" title="4-Androstenediol">4-Androstenediol</a></li>
<li>4-Dehydroepiandrosterone (4-DHEA)</li>
<li>4-Hydroxytestosterone</li>
<li><span class="new">4,17α-Dimethyltestosterone</span></li>
<li>5-Androstenedione</li>
<li>11-Ketotestosterone</li>
<li>11β-Hydroxyandrostenedione</li>
<li><a href="Adrenosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Adrenosterone" title="Adrenosterone">Adrenosterone (11-ketoandrostenedione, 11-oxoandrostenedione)</a></li>
<li><a href="5-Androstenediol.htm" tppabs="https://ptable.com/wiki/compounds/A/5-Androstenediol" title="5-Androstenediol" class="mw-redirect">Androstenediol (5-androstenediol)</a>
<ul><li>Androstenediol 3β-acetate</li>
<li>Androstenediol 17β-acetate</li>
<li>Androstenediol diacetate</li>
<li>Androstenediol dipropionate</li></ul></li>
<li><a href="Androstenedione.htm" tppabs="https://ptable.com/wiki/compounds/A/4-Androstenedione" title="4-Androstenedione" class="mw-redirect">Androstenedione (4-androstenedione)</a></li>
<li>Atamestane</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Boldenone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Boldenone'" tppabs="https://ptable.com/wiki/compounds/A/Boldenone" title="Boldenone">Boldenone</a>
<ul><li>Boldenone undecylenate</li></ul></li>
<li>Boldione (1,4-androstadienedione)</li>
<li><a href="Clostebol.htm" tppabs="https://ptable.com/wiki/compounds/A/Clostebol" title="Clostebol">Clostebol</a>
<ul><li>Clostebol acetate</li>
<li>Clostebol caproate</li>
<li>Clostebol propionate</li></ul></li>
<li>Cloxotestosterone
<ul><li>Cloxotestosterone acetate</li></ul></li>
<li>Dehydroandrosterone</li>
<li><a href="Dehydroepiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone" title="Dehydroepiandrosterone">DHEA (androstenolone, prasterone; 5-DHEA)</a>
<ul><li>DHEA enanthate (prasterone enanthate)</li>
<li><a href="Dehydroepiandrosterone_sulfate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dehydroepiandrosterone_sulfate" title="Dehydroepiandrosterone sulfate">DHEA sulfate</a></li></ul></li>
<li><a href="Exemestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Exemestane" title="Exemestane">Exemestane</a></li>
<li><a href="Formestane.htm" tppabs="https://ptable.com/wiki/compounds/A/Formestane" title="Formestane">Formestane</a></li>
<li>Plomestane</li>
<li>Quinbolone</li>
<li>Silandrone</li>
<li>Testosterone<sup>#</sup> (+dutasteride)
<ul><li>Testosterone esters</li>
<li>Polytestosterone phloretin phosphate</li></ul></li></ul>

<ul><li><i>5α-Dihydrotestosterone derivatives:</i> 1-Androstenediol</li>
<li>1-Androstenedione</li>
<li>1-Androsterone (1-andro, 1-DHEA)</li>
<li>1-Testosterone</li>
<li>3α-Androstanediol</li>
<li>5α-Androst-2-en-17-one</li>
<li>7β-Hydroxyepiandrosterone</li>
<li>11-Ketodihydrotestosterone</li>
<li><a href="Androsterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Androsterone" title="Androsterone">Androsterone</a></li>
<li>Bolazine
<ul><li>Bolazine capronate</li></ul></li>
<li><span class="new">Dihydroethyltestosterone</span></li>
<li>Dihydrofluoxymesterone</li>
<li><span class="new">Dihydromethylandrostenediol</span></li>
<li><a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">Dihydrotestosterone (DHT)</a> (androstanolone, stanolone)
<ul><li>Dihydrotestosterone esters</li></ul></li>
<li><a href="Drostanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drostanolone" title="Drostanolone">Drostanolone</a>
<ul><li>Drostanolone propionate</li></ul></li>
<li><a href="Epiandrosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Epiandrosterone" title="Epiandrosterone">Epiandrosterone</a></li>
<li>Epitiostanol</li>
<li>Mepitiostane</li>
<li>Mesabolone</li>
<li><a href="Mesterolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mesterolone" title="Mesterolone">Mesterolone</a>
<ul><li>Mesterolone cipionate</li></ul></li>
<li>Methyldiazinol</li>
<li>Nisterime
<ul><li>Nisterime acetate</li></ul></li>
<li>Prostanozol</li>
<li>Stenbolone
<ul><li>Stenbolone acetate</li></ul></li>
<li>Testifenon (testiphenon, testiphenone)</li></ul>

<ul><li><i>19-Nortestosterone derivatives:</i> 7α-Methyl-19-norandrostenedione (MENT dione, trestione)</li>
<li>11β-Methyl-19-nortestosterone
<ul><li>11β-Methyl-19-nortestosterone dodecylcarbonate</li></ul></li>
<li>19-Nor-5-androstenediol</li>
<li>19-Nor-5-androstenedione</li>
<li>19-Nordehydroepiandrosterone</li>
<li>Bolandiol
<ul><li>Bolandiol dipropionate</li></ul></li>
<li>Bolandione (19-nor-4-androstenedione)</li>
<li>Bolmantalate (nandrolone adamantoate)</li>
<li>Dienedione</li>
<li>Dienolone</li>
<li>Dimethandrolone
<ul><li>Dimethandrolone buciclate</li>
<li>Dimethandrolone dodecylcarbonate</li>
<li>Dimethandrolone undecanoate</li></ul></li>
<li>LS-1727 (nandrolone 17β-<i>N</i>-(2-chloroethyl)-<i>N</i>-nitrosocarbamate)</li>
<li>Methoxydienone (methoxygonadiene)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Nandrolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Nandrolone'" tppabs="https://ptable.com/wiki/compounds/A/Nandrolone" title="Nandrolone">Nandrolone</a>
<ul><li>Nandrolone esters</li></ul></li>
<li>Norclostebol
<ul><li>Norclostebol acetate</li></ul></li>
<li>Normethandrone (methylestrenolone, normethisterone)</li>
<li><a href="Oxabolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone" title="Oxabolone">Oxabolone</a>
<ul><li><a href="Oxabolone_cipionate.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxabolone_cipionate" title="Oxabolone cipionate">Oxabolone cipionate (oxabolone cypionate)</a></li></ul></li>
<li>Trenbolone
<ul><li>Trenbolone acetate</li>
<li>Trenbolone enanthate</li>
<li>Trenbolone hexahydrobenzylcarbonate</li>
<li>Trenbolone undecanoate</li></ul></li>
<li>Trendione</li>
<li>Trestolone (MENT)
<ul><li>Trestolone acetate</li>
<li>Trestolone enanthate</li></ul></li></ul>

<ul><li><i>5α-Dihydro-19-nortestosterone derivatives:</i> 5α-Dihydronandrolone</li>
<li><span class="new">5α-Dihydrotrestolone</span></li>
<li>19-Norandrosterone</li></ul>

<ul><li><i>17α-Alkylated testosterone derivatives:</i> <a href="Bolasterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Bolasterone" title="Bolasterone">Bolasterone</a></li>
<li><a href="Calusterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Calusterone" title="Calusterone">Calusterone</a></li>
<li>Chlorodehydromethylandrostenediol (CDMA)</li>
<li>Chlorodehydromethyltestosterone (CDMT)</li>
<li>Chloromethylandrostenediol (CMA)</li>
<li>Enestebol</li>
<li>Ethyltestosterone</li>
<li><a href="Fluoxymesterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Fluoxymesterone" title="Fluoxymesterone">Fluoxymesterone</a></li>
<li><a href="Formebolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Formebolone" title="Formebolone">Formebolone</a></li>
<li>Hydroxystenozole</li>
<li>Metandienone (methandrostenolone)</li>
<li>Methandriol (methylandrostenediol)
<ul><li>Methandriol bisenanthoyl acetate</li>
<li>Methandriol diacetate</li>
<li>Methandriol dipropionate</li>
<li>Methandriol propionate</li></ul></li>
<li>Methylclostebol (chloromethyltestosterone)</li>
<li><a href="Methyltestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Methyltestosterone" title="Methyltestosterone">Methyltestosterone</a> (+esterified estrogens)
<ul><li>Methyltestosterone 3-hexyl ether</li></ul></li>
<li>Oxymesterone</li>
<li>Penmesterol</li>
<li>Tiomesterone</li></ul>

<ul><li><i>17α-Alkylated 5α-dihydrotestosterone derivatives:</i> Androisoxazole</li>
<li>Desoxymethyltestosterone</li>
<li><a href="Furazabol.htm" tppabs="https://ptable.com/wiki/compounds/A/Furazabol" title="Furazabol">Furazabol</a></li>
<li>Mebolazine (dimethazine)</li>
<li><a href="Mestanolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mestanolone" title="Mestanolone">Mestanolone</a></li>
<li>Metenolone
<ul><li>Metenolone acetate</li>
<li>Metenolone enanthate</li></ul></li>
<li>Methasterone</li>
<li>Methyl-1-testosterone</li>
<li>Methylepitiostanol</li>
<li>Methylstenbolone</li>
<li><a href="Oxandrolone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxandrolone" title="Oxandrolone">Oxandrolone</a></li>
<li><a href="Oxymetholone.htm" tppabs="https://ptable.com/wiki/compounds/A/Oxymetholone" title="Oxymetholone">Oxymetholone</a></li>
<li><a href="Stanozolol.htm" tppabs="https://ptable.com/wiki/compounds/A/Stanozolol" title="Stanozolol">Stanozolol</a></li></ul>

<ul><li><i>17α-Alkylated 19-nortestosterone derivatives:</i> Bolenol</li>
<li>Dimethyldienolone</li>
<li>Dimethyltrienolone</li>
<li>Ethyldienolone</li>
<li><a href="Ethylestrenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethylestrenol" title="Ethylestrenol">Ethylestrenol</a></li>
<li>Methyldienolone</li>
<li>Methylhydroxynandrolone (MOHN, MHN)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Metribolone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Metribolone'" tppabs="https://ptable.com/wiki/compounds/A/Metribolone" title="Metribolone">Metribolone</a></li>
<li>Mibolerone</li>
<li>Norboletone</li>
<li>Norethandrolone</li>
<li>Propetandrol</li>
<li>RU-2309</li>
<li>Tetrahydrogestrinone</li></ul>

<ul><li><i>17α-Alkylated 5α-dihydro-19-nortestosterone derivatives:</i> 5α-Dihydronorethandrolone</li>
<li>5α-Dihydronormethandrone</li></ul>

<ul><li><i>17α-Vinyltestosterone derivatives:</i> Norvinisterone (vinylnortestosterone)</li></ul>

<ul><li><i>17α-Vinyl-19-nortestosterone derivatives:</i> Vinyltestosterone</li></ul>

<ul><li><i>17α-Ethynyltestosterone derivatives:</i> <a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Danazol  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Danazol'" tppabs="https://ptable.com/wiki/compounds/A/Danazol" title="Danazol">Danazol</a></li>
<li>Ethinylandrostenediol
<ul><li>Ethandrostate</li></ul></li>
<li><a href="Ethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Ethisterone" title="Ethisterone">Ethisterone (ethynyltestosterone)</a></li></ul>

<ul><li><i>5α-Dihydro-17α-ethynyltestosterone derivatives:</i> 17α-Ethynyl-3α-androstanediol</li>
<li>17α-Ethynyl-3β-androstanediol</li>
<li>Dihydroethisterone</li></ul>

<ul><li><i>17α-Ethynyl-19-nortestosterone derivatives:</i> Δ<sup>4</sup>-Tibolone</li>
<li><a href="Desogestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Desogestrel" title="Desogestrel">Desogestrel</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Etonogestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Etonogestrel'" tppabs="https://ptable.com/wiki/compounds/A/Etonogestrel" title="Etonogestrel">Etonogestrel</a></li>
<li>Etynodiol
<ul><li><a href="Etynodiol_diacetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Etynodiol_diacetate" title="Etynodiol diacetate">Etynodiol diacetate</a></li></ul></li>
<li><a href="Gestodene.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestodene" title="Gestodene">Gestodene</a></li>
<li><a href="Gestrinone.htm" tppabs="https://ptable.com/wiki/compounds/A/Gestrinone" title="Gestrinone">Gestrinone</a></li>
<li><a href="Levonorgestrel.htm" tppabs="https://ptable.com/wiki/compounds/A/Levonorgestrel" title="Levonorgestrel">Levonorgestrel</a></li>
<li>Levonorgestrel esters (e.g., levonorgestrel butanoate)</li>
<li>Lynestrenol
<ul><li>Lynestrenol phenylpropionate</li></ul></li>
<li><a href="Norethisterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Norethisterone" title="Norethisterone">Norethisterone</a></li>
<li>Norethisterone esters (e.g., norethisterone acetate, norethisterone enanthate)</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Norgestrel  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Norgestrel'" tppabs="https://ptable.com/wiki/compounds/A/Norgestrel" title="Norgestrel">Norgestrel</a></li>
<li>Norgestrienone</li>
<li>Quingestanol
<ul><li>Quingestanol acetate</li></ul></li>
<li>Tibolone</li></ul>

<ul><li><i>5α-Dihydro-17α-ethynyl-19-nortestosterone derivatives:</i> 5α-Dihydrolevonorgestrel</li>
<li>5α-Dihydronorethisterone</li></ul>

<ul><li><i>Progesterone derivatives:</i> 6α-Methylprogesterone</li>
<li><a href="Medroxyprogesterone_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Medroxyprogesterone_acetate" title="Medroxyprogesterone acetate">Medroxyprogesterone acetate</a></li>
<li>Megestrol acetate</li></ul>

<ul><li><i>Others/unsorted:</i> 3-Keto-5α-abiraterone</li>
<li><a href="Androstane.htm" tppabs="https://ptable.com/wiki/compounds/A/5%CE%B1-Androstane" title="5α-Androstane" class="mw-redirect">5α-Androstane</a></li>
<li>Alternariol</li>
<li>Cl-4AS-1</li>
<li>Drupanol</li>
<li><a href="Trilostane.htm" tppabs="https://ptable.com/wiki/compounds/A/Trilostane" title="Trilostane">Trilostane</a></li>
<li>ZM-182345</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Mixed<br>(<abbr>SARMs</abbr>)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Nonsteroidal:</i> <span class="new">198RL26</span></li>
<li><span class="new">ACP-105</span></li>
<li><span class="new">AC-262536</span></li>
<li>Acetothiolutamide</li>
<li>Andarine (acetamidoxolutamide, androxolutamide, GTx-007, S-4)</li>
<li><span class="new">BMS-564929</span></li>
<li><span class="new">DTIB</span></li>
<li>Enobosarm (ostarine, MK-2866, GTx-024, S-22)</li>
<li><span class="new">FTBU-1</span></li>
<li>GSK2881078</li>
<li><span class="new">GSK-4336A</span></li>
<li><span class="new">GSK-8698</span></li>
<li>LG-121071 (LGD-121071)</li>
<li>LGD-2226</li>
<li><span class="new">LGD-2941 (LGD-122941)</span></li>
<li>LGD-3303</li>
<li>LGD-4033</li>
<li>LY-2452473</li>
<li><span class="new">JNJ-26146900</span></li>
<li>JNJ-28330835</li>
<li><span class="new">JNJ-37654032</span></li>
<li><span class="new">ORM-11984</span></li>
<li><span class="new">R-1</span></li>
<li>RAD140</li>
<li>RU-59063</li>
<li><span class="new">S-1</span></li>
<li>S-23</li>
<li>S-40503</li>
<li><span class="new">S-101479</span></li>
<li>Triclosan</li></ul>

<ul><li><i>Steroidal:</i> <span class="new">EM-9017</span></li>
<li>MK-0773</li>
<li>TFM-4AS-1</li>
<li>YK-11</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center">Antagonists</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Steroidal:</i> 7α-Thioprogesterone</li>
<li>7α-Thiospironolactone</li>
<li>7α-Thiomethylspironolactone</li>
<li>11α-Hydroxyprogesterone</li>
<li>15β-Hydroxycyproterone acetate</li>
<li>Abiraterone</li>
<li>Abiraterone acetate</li>
<li>Allyltestosterone</li>
<li>Benorterone</li>
<li>BOMT</li>
<li>Canrenoic acid</li>
<li>Canrenone</li>
<li>Chlormadinone acetate</li>
<li>Clascoterone</li>
<li>Clometerone</li>
<li><a href="Cyproheptadine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproheptadine" title="Cyproheptadine">Cyproheptadine</a></li>
<li><a href="Cyproterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Cyproterone" title="Cyproterone">Cyproterone</a></li>
<li>Cyproterone acetate</li>
<li>Delanterone</li>
<li>Delmadinone acetate</li>
<li>Dicirenone</li>
<li>Dienogest</li>
<li><a href="Drospirenone.htm" tppabs="https://ptable.com/wiki/compounds/A/Drospirenone" title="Drospirenone">Drospirenone</a></li>
<li>DU-41165</li>
<li>Edogestrone</li>
<li><span class="new">EM-4350</span></li>
<li>EM-5854</li>
<li><span class="new">EM-5855</span></li>
<li><span class="new">EM-6537</span></li>
<li>Epitestosterone</li>
<li>Galeterone</li>
<li>Guggulsterone</li>
<li>Medrogestone</li>
<li>Megestrol acetate</li>
<li>Mespirenone</li>
<li>Metogest</li>
<li>Mexrenone</li>
<li><a href="Mifepristone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mifepristone" title="Mifepristone">Mifepristone</a></li>
<li>Nomegestrol acetate</li>
<li>Nordinone</li>
<li>Osaterone</li>
<li>Osaterone acetate</li>
<li>Oxendolone</li>
<li>Potassium canrenoate</li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Promegestone  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Promegestone'" tppabs="https://ptable.com/wiki/compounds/A/Promegestone" title="Promegestone">Promegestone</a></li>
<li>Prorenone</li>
<li>Rosterolone</li>
<li><span class="new">RU-15328</span></li>
<li>SC-5233 (spirolactone)</li>
<li><a href="Spironolactone.htm" tppabs="https://ptable.com/wiki/compounds/A/Spironolactone" title="Spironolactone">Spironolactone</a></li>
<li>Spirorenone</li>
<li>Spiroxasone</li>
<li>Topterone</li>
<li>Trimegestone</li>
<li>Trimethyltrienolone (R-2956)</li>
<li>Zanoterone</li></ul>

<ul><li><i>Nonsteroidal:</i> 5<i>N</i>-Bicalutamide</li>
<li>AA560</li>
<li><span class="new">Antarlides</span></li>
<li><span class="new">Arabilin</span></li>
<li>Apalutamide</li>
<li>Atraric acid</li>
<li><span class="new">AZD-3514</span></li>
<li>Bakuchiol</li>
<li><span class="new">BAY-1024767</span></li>
<li><a href="Bicalutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Bicalutamide" title="Bicalutamide">Bicalutamide</a></li>
<li><a href="Bisphenol.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol" title="Bisphenol">Bisphenols</a> (e.g., <a href="Bisphenol_A_diglycidyl_ether.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A_diglycidyl_ether" title="Bisphenol A diglycidyl ether">BADGE</a>, <span class="new">BFDGE</span>, <a href="Bisphenol_A.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_A" title="Bisphenol A">bisphenol A</a>, bisphenol F, <a href="Bisphenol_S.htm" tppabs="https://ptable.com/wiki/compounds/A/Bisphenol_S" title="Bisphenol S">bisphenol S</a>)</li>
<li><span class="new">BMS-501949</span></li>
<li><span class="new">BMS-570511</span></li>
<li>BMS-641988</li>
<li><span class="new">CH5137291</span></li>
<li><a href="Cimetidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Cimetidine" title="Cimetidine">Cimetidine</a></li>
<li>Cioteronel</li>
<li>Cyanonilutamide</li>
<li>Darolutamide</li>
<li>DDT (via metabolite p,p’-DDE)</li>
<li><a href="Dieldrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Dieldrin" title="Dieldrin">Dieldrin</a></li>
<li>DIMP</li>
<li><a href="Endosulfan.htm" tppabs="https://ptable.com/wiki/compounds/A/Endosulfan" title="Endosulfan">Endosulfan</a></li>
<li>Enzalutamide</li>
<li>EPI-001</li>
<li>EPI-7386</li>
<li><a href="Fenarimol.htm" tppabs="https://ptable.com/wiki/compounds/A/Fenarimol" title="Fenarimol">Fenarimol</a></li>
<li><a href="Flutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Flutamide" title="Flutamide">Flutamide</a></li>
<li>Hydroxyflutamide</li>
<li>Inocoterone</li>
<li>Inocoterone acetate</li>
<li><a href="Ketoconazole.htm" tppabs="https://ptable.com/wiki/compounds/A/Ketoconazole" title="Ketoconazole">Ketoconazole</a></li>
<li>Ketodarolutamide</li>
<li>Lavender oil</li>
<li><span class="new">LG-105</span></li>
<li>LG-120907</li>
<li><span class="new">LGD-1331</span></li>
<li>Linuron</li>
<li><a href="Methiocarb.htm" tppabs="https://ptable.com/wiki/compounds/A/Methiocarb" title="Methiocarb">Methiocarb</a></li>
<li><span class="new"><i>N</i>-Butylbenzenesulfonamide</span></li>
<li><i>N</i>-Desmethylapalutamide</li>
<li><i>N</i>-Desmethylenzalutamide</li>
<li><a href="Nilutamide.htm" tppabs="https://ptable.com/wiki/compounds/A/Nilutamide" title="Nilutamide">Nilutamide</a></li>
<li><span class="new">ONC1-13B</span></li>
<li>Pentomone</li>
<li><span class="new">PF-998425</span></li>
<li><a href="Phenothrin.htm" tppabs="https://ptable.com/wiki/compounds/A/Phenothrin" title="Phenothrin">Phenothrin</a></li>
<li>Prochloraz</li>
<li><a href="Procymidone.htm" tppabs="https://ptable.com/wiki/compounds/A/Procymidone" title="Procymidone">Procymidone</a></li>
<li>Proxalutamide</li>
<li>Ralaniten (EPI-002)</li>
<li>Ralaniten acetate (EPI-506)</li>
<li>RD-162</li>
<li><span class="new">Ro 2-7239</span></li>
<li><span class="new">Ro 5-2537</span></li>
<li>RU-22930</li>
<li>RU-56187</li>
<li>RU-57073</li>
<li>RU-58642</li>
<li>RU-58841</li>
<li>Seviteronel</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li>Topilutamide (fluridil)</li>
<li><a href="Valproic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Valproic_acid" title="Valproic acid" class="mw-redirect">Valproic acid</a></li>
<li>Vinclozolin</li>
<li><span class="new">YM-580</span></li>
<li><span class="new">YM-92088</span></li>
<li><span class="new">YM-175735</span></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><abbr>GPRC6A</abbr></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:6em;;text-align:center;">Agonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Cations (incl. aluminum, <a href="Calcium.htm" tppabs="https://ptable.com/wiki/compounds/A/Calcium" title="Calcium">calcium</a>, <a href="Gadolinium.htm" tppabs="https://ptable.com/wiki/compounds/A/Gadolinium" title="Gadolinium">gadolinium</a>, <a href="Magnesium.htm" tppabs="https://ptable.com/wiki/compounds/A/Magnesium" title="Magnesium">magnesium</a>, <a href="Strontium.htm" tppabs="https://ptable.com/wiki/compounds/A/Strontium" title="Strontium">strontium</a>, <a href="Zinc.htm" tppabs="https://ptable.com/wiki/compounds/A/Zinc" title="Zinc">zinc</a>)</li>
<li>Dehydroandrosterone</li>
<li><a href="Dihydrotestosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dihydrotestosterone" title="Dihydrotestosterone">Dihydrotestosterone</a></li>
<li><a href="Estradiol.htm" tppabs="https://ptable.com/wiki/compounds/A/Estradiol" title="Estradiol">Estradiol</a></li>
<li><small>L</small>-α-Amino acids (incl. <a href="Arginine.htm" tppabs="https://ptable.com/wiki/compounds/A/Arginine" title="Arginine"><small>L</small>-arginine</a>, <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine"><small>L</small>-lysine</a>, <a href="Ornithine.htm" tppabs="https://ptable.com/wiki/compounds/A/Ornithine" title="Ornithine"><small>L</small>-ornithine</a>)</li>
<li>Osteocalcin</li>
<li><abbr>SHBG</abbr></li>
<li><a href="Testosterone.htm" tppabs="https://ptable.com/wiki/compounds/A/Testosterone" title="Testosterone">Testosterone</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2"><div>
<dl><dt>See also</dt>
<dd>Receptor/signaling modulators</dd>
<dd>Androgens and antiandrogens</dd>
<dd>Estrogen receptor modulators</dd>
<dd>Progesterone receptor modulators</dd>
<dd>List of androgens/anabolic steroids</dd></dl>
</div></td></tr></tbody></table></div><span>
</span>










<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-04-15" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Nilutamide&oldid=951045645  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Nilutamide&oldid=951045645'" tppabs="https://en.wikipedia.org/wiki/?title=Nilutamide&oldid=951045645">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>